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Tuberculosis (TB) remains a world pandemic, claiming the lives of 1.7 million people 
in 2017. Several risk factors have been identified as key attributes to the development 
of TB, such as type 2 diabetes (T2D). Cellular function of immune cell types are altered 
in TB-T2D patients compared to TB patients, leaving the host vulnerable to increased 
Mycobacterium tuberculosis (Mtb) replication and enhanced disease severity. 
Emphasis has been placed on the role of T-cells and macrophages in TB-T2D 
comorbidity, however, B-cells also play a fundamental role in the adaptive immune 
response to TB. Since limited information is available on the frequency of B cells in TB 
in the context of T2D, we aimed to determine the frequencies of regulatory and killer 
B-cell, through the expression of the cell surface markers, FasL (CD178+) and IL-5Rα
(CD125+). In addition, we investigate imbalances in host immune markers in healthy 
controls, T2D patients and TB patients with and without T2D. The immunological 
responses, including regulatory, memory and apoptotic B-cell function, are impaired 
in T2D, TB and TB-T2D patients at the initiation of TB treatment, and improve in TB 
and TB-T2D patients following two months into anti-TB treatment. In addition, markers 
associated with cell proliferation, cell development, chemotactic function, granuloma 
formation and monocyte recruitment are impaired, highlighting the need for effective 





Tuberkulose (TB) bly 'n wêreldpandemie wat die lewens van 1,7 miljoen mense in 
2017 geëis het. Verskeie risikofaktore is geïdentifiseer as sleutelkenmerke vir die 
ontwikkeling van TB, soos tipe 2-diabetes (T2D). Die sellulêre funksie van 
immuunselle in TB-T2D-pasiënte is anders in vergelyking met TB-pasiënte, wat die 
gasheer kwesbaar maak vir verhoogde Mycobacterium tuberculosis (Mtb) replikasie 
en die erns van die siekte verhoog. Klem is gelê op die rol van T-selle en makrofage 
in die TB-T2D mede-morbiditeit. B-selle speel egter ook 'n fundamentele rol in die 
aanpasbare immuunrespons op TB. Aangesien beperkte inligting beskikbaar is oor 
die frekwensie van B-selle in TB in die konteks van T2D, het ons ten doel gehad om 
die frekwensies van regulatoriese en moordenaar B-selle te bepaal, deur die 
uitdrukking van die seloppervlakte-merkers, FasL (CD178+) en IL-5Rα (CD125+) te 
meet. Daarbenewens ondersoek ons wanbalanse in die gasheer immuunmerkers in 
gesonde kontroles, T2D-pasiënte en TB-pasiënte met en sonder T2D. Die 
immunologiese reaksies, insluitend regulatoriese, geheue en apoptotiese B-
selfunksie, word aangetas in T2D-, TB- en TB-T2D-pasiënte voor die aanvang van TB 
behandeling, en verbeter in die TB- en TB-T2D-pasiënte na twee maande van TB 
behandeling.  Verder word merkers wat verband hou met selproliferasie, 
selontwikkeling, chemotaktiese funksie, granuloomvorming en monosiet-werwing 
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Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb), a bacterium that has infected 1.7 billion people in the world according to the 
2018 World Health Organization (WHO) global TB report. It is reported that only 5-
10% of infected individuals will develop active TB disease in their lifetime (WHO global 
TB report, 2018). This is, however, still problematic as 10 million people are affected 
by this disease annually, claiming the lives of more than 1.3 million people yearly. TB 
incidence rates are the highest on the African and Asian continents in comparison to 
other continents on the globe with Sub-Saharan Africa and South East Asia mostly 
impacted (Figure 1.1). In efforts to eradicate the TB pandemic, the WHO has called 
for zero TB by 2035. Researchers reacted to this call for action and have made great 
strides towards improved diagnostic tools and treatment regimens. However, the 
immune response against Mtb still remains partially understood.  
 
Figure 1. 1: The Global incidence rates reported in East Asia region with more than 300 




The transmission of Mtb begins with the inhalation of an Mtb containing droplet 
expectorated by individuals with TB. The bacteria travels to the alveoli where they 
encounter large phagocytes known as alveolar macrophages (Cohen et al., 2018). 
The recognition of Mtb by phagocytic cells is essential for the activation of phagocytic 
cells and initiation of the innate immune response (Cohen et al., 2018) This is achieved 
through the interaction of the mycobacteria with Toll-like receptors (TLRs). TLRs are 
a type of pathogen recognition receptors (PRRs) expressed on various innate immune 
cells such as macrophages, dendritic cells (DCs), natural killer (NK) cells and cells of 
the adaptive immune response including B and T lymphocytes (Reviewed by Janssens 
and Beyaert, 2003). Other PRRs include nucleotide-binding oligomerization domain 
(NOD) Like Receptors, C-Type Lectins and Dectin-1. They recognize highly conserved 
structural motifs shared by pathogens known as pathogen-associated molecular 
patterns (PAMPs). The signalling of TLRs occurs through the induction of the adaptor 
molecular MyD88, which is responsible for the activation of the mitogen-activated 
protein kinase (MAPKs) and nuclear factor kappa B (NF-кB) pathways (Hemmi et al., 
2000). In the presence of Mtb these pathways induce the production of inflammatory 
cytokines and upregulate co-stimulatory molecules of antigen presenting cells (APCs) 
(Blander and Medzhitov, 2004; Li et al., 2009).  
Antigen presenting cells express major histocompatibility complex (MHC) class II on 
their cell surface and these immune cells are phagocytes; macrophages, DCs and 
antibody producing B cells. Mtb bacilli are taken up by APCs, degraded in the 
endocytic pathway and presented on MHC class II molecules on the surface of the 
APCs. Macrophages and DCs recognize and internalize the pathogen through 
phagocytosis. Inside the phagosome there are lysosomes with antimicrobial enzymes, 
degradative peptides and proteases, which degrade the pathogen into peptides for 
antigen presentation (Arcos et al., 2017). Mtb is however able to prevent the fusion of 
the lysosome and phagosome to increase its survival in the cells (Sundaramurthy et 
al., 2017). 
Alveolar macrophages are the first APCs Mtb encounter in the alveoli, their primary 
objective is to clear Mtb, however, some bacilli are persistent and can survive and 
replicate inside the macrophages. In efforts to eradicate Mtb, infected alveolar 
macrophages produce cytokines and recruit other immune cells like neutrophils, NK 




tissue remodelling and inflammation in the lung that results in the formation of 
granulomas (Volkman et al., 2010). The granuloma is a complex of immune cells 
where the exterior cuff consists of lymphocytes and the core of epithelioid 
macrophages and multinucleated giant cells. Should the bacteria persist, the centre 
becomes necrotic and rich in lipid content (Marakalala et al., 2016), which is utilized 
by Mtb as a carbon source (Menon et al., 2019) aiding their survival and replication in 
the lung. Subsequently, necrotic granulomas can rupture into the airways that leads 
to the spread of Mtb within the lung and to other organs.  
The recognition of Mtb infected macrophages by T cells is essential for the 
containment of the mycobacteria. However, in the presence of Mtb, T cell recruitment 
and responses are delayed, promoting the survival of persistent Mtb in the lung 
(Chackerian et al., 2002). T helper 1 (Th1) cells, a subset of CD4+ T cells, activate 
macrophages through the production of interferon gamma (IFN-γ) and tumor necrosis 
factor alpha (TNF-α), inducing apoptosis of the Mtb infected cells and inflammation 
(Lyadova and Panteleev, 2015; Sallin et al., 2017). TNF-α is involved in systemic 
inflammation and enhances the migration of immune cells to the site of infection (Butler 
et al., 2017). IFN-γ, produced by Th1 cells, does not only enhance the microbicidal 
activity of macrophages but also the expression of inducible nitric oxide synthase 
(iNOS) intermediates (Tötemeyer et al., 2006; Braverman and Stanley, 2017). This 
highlights the role of cytokines in coordinating an immune response by initiating the 
recruitment and activation of the immune cells to the Mtb infected areas of the lung. 
2. Type 2 Diabetes 
Type 2 diabetes (T2D) is a metabolic disorder characterized by high blood glucose 
and insulin resistance. The prevalence of T2D is on a constant rise in low- and middle-
income countries, due to the reduced intake of nutritional foods and lack of physical 
activity. It is also heavily correlated to social-economic factors found in low- and 
middle-income countries with people living in these countries having an increased risk 
of developing T2D (Remais et al., 2013). According to the International Diabetes 
Foundation (IDF) 2017 report, the number of people living with T2D will increase with 
156% in Sub-Saharan Africa by 2045 (Figure 1.2). In no other region in the world is 




population are currently not aware of their T2D status and therefore remain 
undiagnosed (IDF 2017). 
 
Figure 1. 2: Estimated increases in global diabetes prevalence. The graph highlights the prevalence 
of diabetes in the different regions of the world. In 2017, the Western Pacific region had the highest 
number of people living with diabetes; yet, by 2045 the greatest increase in people living with diabetes 
will be seen in the Sub-Saharan African region. More than a 2-fold increase in the numbers of patients 
with diabetes, the highest globally, will be seen in this region (IDF diabetes atlas - 2017 Atlas). 
Glucose homeostasis is regulated by metabolic pathways, gluconeogenesis and 
glycogenolysis. The former is responsible for the generation and storage of glucose 
and the latter for the breakdown of glycogen. These metabolic pathways are 
responsible for the maintenance of blood glucose in the body. Elevated blood glucose 
signals the pancreatic β cells to release insulin (Tomás et al., 2002). Insulin, in turn, 
regulates the absorption of glucose in the liver, fat tissue and skeletal muscle cells 
(Tomás et al., 2002). The uptake of glucose in these tissues is regulated by specific 
glucose transporters with GLUT-1 and GLUT-4 being two distinct glucose transporters 
in muscle tissue (Barnard and Youngren, 1992). During hyperglycaemia, the binding 
of insulin to the insulin receptor upregulates the PI3K/AKT signalling cascade resulting 
in the increased expression of GLUT4 and downregulation of the gluconeogenesis 
pathway (Huang et al., 2018; Watson and Pessin, 2006). GLUT4 then translocates to 




so decreasing the blood glucose levels (Watson and Pessin, 2006). Hyperglycaemia 
observed during T2D leads to an increase in β cell activity, enhancing cell mass and 
insulin secretion due to the high demand for insulin production. 
T2D is associated with obesity and low-grade chronic inflammation with increased 
expression of pro-inflammatory cytokines and adipokines such as interleukin-1 beta 
(IL-1β), IL-6, TNFα and leptin (Reviewed by Wieser et al., 2013). Systemic C-reactive 
protein (CRP) levels for example are directly correlated with a higher HbA1c in T2D 
(King et al., 2003). Metabolic stresses such oxidative stress and endoplasmic 
reticulum (ER) stress promote inflammation resulting in the development of insulin 
resistance. In T2D oxidative stress is induced through the production of reactive 
oxygen species (ROS) and the decreased levels of antioxidative enzymes in impaired 
β cells leaves the host vulnerable to oxidative stress (Evans et al., 2003). In the 
presence of hyperglycaemia there is a drastic demand for insulin production and 
insulin influx through the ER of β cells induces ER stress (Scheuner et al., 2005). Other 
factors contributing to the inflammation observed include free fatty acids (FFA) and 
advanced glycation end products (AGEs), which are elevated in T2D patients. They 
bind to specific cell receptors such as TLRs and RAGE (Syed et al., 2018). 
Obesity is a major risk factor for T2D and contributes to the increase in basal cytokine 
levels and chronic inflammation in T2D. The secretion of cytokines and chemokines 
from the adipose tissue into the blood stream promotes inflammation in other tissues 
such as the skeleton muscle. Cytokines produced by the adipose tissue, causes the 
migration of immune cells into the adipose tissue, inducing the phenotypic switching 
of macrophages into pro-inflammatory M1 macrophages (Fujisaka et al., 2009; 
Lumeng et al., 2007). The dysregulated immune response associated with T2D is also 
apparent in the chronic activation of T cells due to the hyperglycaemia (Richard et al., 
2017) and in an attempt to maintain normal physiological cytokine responses. The 
altered adaptive immune responses and chronic inflammation present in obese T2D 
is correlated with increased susceptibility respiratory infections such as Streptococcus 
pneumoniae (Martinez et al., 2014), klebsiella pneumoniae (Martinez et al., 2016) and 




3. Tuberculosis and Type 2 Diabetes 
T2D is a risk factor for TB (Jeon and Murray, 2008). Individuals who are latently 
infected with Mtb have a 3 to 8-fold increased chance of progressing from latent 
infection to active TB disease (Restrepo et al., 2011). This is a major concern as it is 
estimated that a quarter of the world’s population is latently infected with Mtb with most 
of these individuals living in countries with an estimated increase in T2D prevalence 
(Figure 1.1 and Figure 1.2) (Getahun et al., 2015; Houben and Dodd, 2016; WHO, 
Tuberculosis, 2018). 
T2D patients with poorly controlled hyperglycaemia (HbA1c greater than 8%) have an 
even greater risk of progressing to active TB disease in comparison to T2D patients 
with controlled glycaemia (Vallerskog et al., 2010). When patients with T2D develop 
TB, they have a higher bacterial load and there is a delay in their sputum culture 
conversion two months into TB treatment in comparison to TB patients without T2D 
(Jeon and Murray, 2008a; Riza et al., 2016; Stevenson et al., 2007). They are also 
more likely to fail TB treatment, experience recurrent disease and have a higher 
mortality rate in comparison to TB patients without T2D (Dooley et al., 2009). 
3.1 T cells 
T cells originate from the bone marrow and migrate to the thymus where maturation is 
completed. The maturated T lymphocytes enter the bloodstream and the peripheral 
lymphoid organs where they encounter antigens presented by MHC II molecules. The 
T cell receptor (TCR) exists in two forms with 95% of T cells containing the alpha and 
beta (αβ) subunit while the remaining 5 % have the gamma and delta (γδ) subunit 
(Andreu-Ballester et al., 2013). CD4 and CD8 are co-receptors that are bound at 
distinct regions on the MHC class II and MHC class I molecules, respectively. Binding 
of the co-receptors brings the cytoplasmic tails of these receptors in close proximity to 
the cytoplasmic tail of the TCR containing the immune receptor tyrosine-based 
activation motifs (ITAMs). The co-receptor linked tyrosine kinase, Lck, phosphorylates 
the ITAM initiating the TCR signalling cascade (Gaud et al., 2018). Therefore, in order 
for T cells to recognize Mtb peptides and to become activated, it requires the 
presentation of peptides to MHC class II molecules and the interaction between the 




When T cells encounter Mtb they are activated and polarize into effector and memory 
T cells. Memory immune cells evoke a rapid reactivation of effector cells, increased 
immune cell proliferation and they evoke a rapid adaptive immune response. However, 
pathogen persistence and chronic inflammation can result to T cell exhaustion. Persist 
antigen exposure over a long period of time alters memory T cell functionality (Han et 
al., 2010). During T cell exhaustion, the cytokines secreted by effector T cells is 
suppressed and T cell proliferation is reduced (Day et al., 2014). A similar trend is also 
evident in TB-T2D patients were memory T cells are increased and the frequency of 
the naïve and effector T cells are decreased (Kumar et al., 2016). 
3.2 B cells 
B cells are a subset of leukocytes derived from stem cells in the bone marrow. The 
multipotent stem cells are found in the bone marrow differentiate into lymphoid and 
then into B cell progenitors (Zou et al., 2017). After maturation, B lymphocytes enter 
circulation and encounter antigens in the peripheral lymphoid organs. Once activated, 
B cells undergo B cell differentiation and clonal expansion (Figure 1.3A). The principal 
of clonal expansion is for activated B cells to express antigen specific receptors with 
an increased binding affinity and specificity as the parent antigen. 
 
Figure 1. 3: The immunological mechanisms of B cells. A) Antigen presentation: The APC function 
of B cells through T cell interaction resulting in somatic hypermutation, B cell expansion and 
development of memory B cells and antibody producing B cells. B) B cells produce cytokines to mediate 
an immune response and influence the effector functions of immune cells. C) B cells produce antibodies 
which can regulate the innate and adaptive immune response. Key: maroon double Y: B cell receptor, 
red oval: pathogen, purple circles: cytokines, green Y, pink double Y and blue snowflake: 
Immunoglobulins. Image adapted from (Chan et al., 2014). 




The B cell receptor (BCR) like the TCR consists of a transmembrane and cytoplasmic 
domain. Intracellular signalling is transmitted by two accessory proteins Igα and Igβ 
which form a heterodimer and contains the ITAMs (Murphy et al., 2012). The B cell 
co-receptor complex consisting of CD19, CD21 (CR2) and CD81 (TAPA-1) provides 
additional activation signals through binding of CD21 to C3d-tagged antigens on the 
immunoglobulin. The cross-link between the co-receptors and the BCR induces 
phosphorylation of tyrosine kinase on the cytoplasmic tail of CD19 initiating a 
secondary signalling pathway through the phosphorylation of PI 3-kinases. The 
interaction between BCR and the co-receptors serves to strengthen intracellular 
signalling upon antigen recognition. B cells furthermore undergo T cell-dependent 
activation whereby a second activation signal is generated when the CD40 molecule 
on the B cells interacts with the CD40 ligand (CD40L) on activated T cells. Upon 
activation, B cells undergo clonal expansion and differentiate into memory B cells and 
antibody producing plasma cells and secrete cytokines (Figure 1.3). B cell cytokine 
responses are known to play an important role in responses against TB (du Plessis et 
al., 2016). 
As stipulated above, the function of B cells has been defined in terms of its role when 
the immune system encounters a foreign invasion, but this mechanism occurs in 
conglomerate with other immune responses because B cells cannot eradicate Mtb 
from the host in isolation. During TB, B cells accumulate in follicle-like aggregates at 
the periphery of the granuloma while some penetrate the granuloma structure where 
they influence immune responses against Mtb (Ulrichs et al., 2005, 2004). In the 
absence of B cells, their APC function is altered in the granuloma, there is a decrease 
in the differentiation and frequency of Mtb specific T cells in the granuloma (Phuah et 
al., 2016). B cells can modulate immune responses in the granuloma during Mtb 
infection. The decreased frequency of circulating B cells in the peripheral of TB 
patients could possibly account for the dissociation in the granuloma. Patients with TB 
have a lower frequency of B cells and their frequency and proliferation ability is 
restored after TB treatment (Joosten et al., 2016). 
3.2.1 Memory B cells 
Memory B cells are generated in the germinal center in secondary lymphoid tissues 




naïve B cells which include; a longer lifespan, rapid and enhanced secondary immune 
responses upon a re-encounter with a specific antigen and robust clonal expansion. 
In TB patients, memory B cell frequencies are decreased and their role in the adaptive 
immune response is downregulated (Joosten et al., 2016). However, the frequency of 
plasma B cells which differentiated from B memory cells remain unchanged in patients 
infected with Mtb and in patients with TB (Joosten et al., 2016). A similar trend was 
observed in obese T2D patients where the frequency of resting memory B cells 
decreased in comparison to healthy individuals while the plasma cell frequencies 
remained unchanged (CD19+CD27+)  
3.2.2 Regulatory B cells 
Invading pathogens and the presence of tissue damage generally induces an 
inflammatory response to clear the pathogen or to repair any occurrence of tissue 
damage. However, if this inflammation remains constant and unchecked it can be 
pathogenic to the host. The immune system counteracts this through the release of 
anti-inflammatory cytokines and the cells from which they are secreted are called 
immunosuppressive cells which have immune-regulatory function (Medzhitov, 2008).  
During inflammation, there are defects in the circulation of these suppressor cells 
(Vered et al., 2013). The B cell subset associated with this immunosuppressive 
function are known as regulatory B cells (Bregs). B cells account for 2-10% of all 
immune cells in human whole blood and an even lower frequency are Bregs (<1%) 
(Iwata et al., 2011). Bregs originate from transitional 2 marginal zone precursor B cells, 
these are immature B cells occurring during B cell developmental stage. After B cell 
maturation, B cells migrate from the bone marrow to the spleen where they 
differentiate into transitional type 1 or type 2 B cells.  
The phenotype of Bregs is characterized by the secretion of anti-inflammatory cytokine 
IL-10 and the production of IgM (Mauri and Bosma, 2012). Bregs have been primarily 
studied in autoimmune diseases where their frequency is higher in comparison to the 
absence of autoimmunity (Blair et al., 2010; Correale et al., 2008). IL-10 dependent 
CD19+CD24hiCD38hi Breg phenotype suppresses Th1 responses and Th17 
differentiation (Blair et al., 2010; Flores-Borja et al., 2013). The suppressive ability of 
Bregs is expressed through the secretion of IL-10 and transforming growth factor-β 




CD19+CD24hiCD38hi Breg expressing CD1dhi and IgD inhibit the production of IFN-γ 
and TNF-α through CD4+T cell activation. (Lemoine et al., 2011). Bregs control the 
production of excessive pro-inflammatory cytokines through inhibiting the 
differentiation of CD4+T cells into Th1 and Th17 (Flores-Borja et al., 2013). The 
continuous exposure of Bregs to pro-inflammatory cytokines IL-1β and IL-6 impair their 
development and suppressive ability (Flores-Borja et al., 2013).  
An alternative mechanism for B cells to regulate their immunosuppressive properties 
is through the expression of the death-inducing ligand FasL (CD178). FasL is a 
membrane bound protein belonging to the TNF-family and the Fas/FasL pathway 
mediates lymphocyte apoptosis (Zuñiga et al., 2002). B cells expressing Fas on their 
cell surface bind to target cells expressing Fas, activating the Fas/FasL cascade 
induce apoptosis of the target cell. (Lundy et al., 2001).  
3.2.3 Regulatory B cells in TB 
The regulatory function of B cells can also be induced by IL-5, the surface expression 
of IL-5 receptor alpha (IL-5rα) is higher in FasL+ expressing B cells in comparison to 
FasL- B cells (Klinker et al., 2013). The expression of both FasL+ IL-5rα in Bregs in TB 
patients increases with TB treatment. This could be suggestive of a protective role that 
the expression of FasL has because B cells expressing FasL can induce apoptosis 
and probably induce the apoptosis of Mtb (van Rensburg et al., 2017). A similar trend 
was observed in killer Bregs expressing the phenotype CD19+CD38+IgM+FasL+IL5Rα 
(van Rensburg et al., 2017).  
3.3 B cells in T2D 
In patients with T2D the depletion of B cells was correlated with a decline in Th17 
proliferation and an increased production of pro-inflammatory cytokines (Cao et al., 
2016). Furthermore, B cells are implemented in the progression of insulin resistance 
in T2D through the activation of Th1 and Th17 cells and the release of IgG an antibody 
elevated during the presence of a pathogen within the host (DeFuria et al., 2013). The 
secretion of Th2 cells suppress the inflammatory effects of Th1 cells through 
stimulating the differentiation of B cells into plasma cells and memory B cells to 
enhance an immune response (Cao et al., 2016). The frequency of circulating naïve 
B cells is higher while memory B cells were lower in patients with T2D when compared 




The mechanism and effectiveness of B cells is impaired in TB and this is evident 
through the reduction of naïve and memory B cells, the secretion of pro-inflammatory 
cytokines and the decrease of immunosuppressive Bregs mediated by IL-10. In T2D 
the defects in B cells has been associated with obesity and insulin resistance with 
limited research done to examine the effects of hyperglycaemia on these cells. Little 
is known about the role of B cells in TB patients with T2D (TB-T2D). Preliminary data 
generated in our research group suggest that the absolute number of B cells in TB-
T2D patients are altered in comparison to TB patients without T2D (unpublished). To 
our knowledge the only published work on B cells in TB-T2D was conducted by Kumar 
et al where the frequency of naïve B cells was decreased. B cells are important 
contributors of the adaptive immune response, yet little is known about their function 





Aims and Objectives 
Hypothesis 
We hypothesize that the frequency of B and T cell subsets as well as peripheral 
cytokine responses will be altered in TB patients with and without T2D. 
Aim 
The aim of this study was to investigate the phenotypic profile of B and T cell subsets 
in TB patients with and without T2D and their peripheral cytokine responses. 
Objectives 
1. To phenotype B and T cells isolated from the whole blood of TB patients with 
and without T2D through cell surface staining of cells collected at baseline (prior 
to initiation of TB treatment) and month two of TB treatment. 
2. To investigate peripheral cytokine concentrations of TB patients with and 






1. Ethics statement 
This research study was conducted in accordance with the ethical principles for 
research established by the Declaration of Helsinki, the International Conference of 
Harmonization (ICH) and Good Clinical Practice (GCP) guidelines. 
Ethical approval for the ALERT (N13/05/O64A), TANDEM (N13/05/064) and Screen 
TB (N16/05/070) studies were obtained from the Health Research Ethics Committee 
(HREC) of Stellenbosch University as well as the City of Cape Town City Health. 
Informed consent specifying clinical and research laboratory procedures were read 
and explained by study coordinators and signed by participants. 
2. Participate recruitment  
2.1 Study participants 
For this cross-sectional study, participants were recruited from clinics surrounding 
Tygerberg Hospital (Fisantekraal, Ravensmead, Uitsig, Adriaanse and Sarepta) in the 
Western Cape. Recruited participants were enrolled into the ALERT, TANDEM and 
Screen TB studies if they met the study specific inclusion criteria. Close contacts (CCs) 
of TB patients with and without T2D, were enrolled in the ALERT study. Healthy 
controls and TB patients, both with and without T2D were enrolled in the TANDEM 
study. As part of this study TB patients (TB and TB-T2D) were followed up during TB 
treatment. For the Screen TB study, participants that presented with symptoms 
suggestive of TB were recruited and followed up during TB treatment. Participants who 
presented with symptoms suggestive of TB including, cough, fever, haemoptysis, 
chest pains, night sweats, loss of appetite, weight loss, malaise were included in the 
study. 
Participants were between the age of 18 and 65 were excluded if they were HIV 
positive, pregnant or breastfeeding, had a haemoglobin less than 9g/L, were currently 
on TB treatment or received TB treatment 90 days prior to recruitment, used antibiotics 




corticosteroids 60 days prior to recruitment or presented with infectious disease other 
than TB and ulcerations were excluded. T2D was diagnosed as haemoglobin A1c 
(HbA1c) ≥ 6.5%. 
2.2 Selection of participants 
Serum samples of 59 participants were included for luminex analysis (Section 3). 
Thirty-four were TB cases and five were TB-T2D patients, twenty-five of the TB cases 
and two of the TB-T2D patients had a month two follow up. Eleven T2D patients (4 
QFN positive and 7 QFN negative) and nine healthy controls (HC) (all QFN positive) 
were also included (Figure 2.1). Cryopreserved whole blood of 54 participants were 
selected for the phenotypic analysis of B cells (Section 4). Of the 54 participants, 15 
were TB cases and three TB-T2D patients, 11 of the TB patients were followed up two 
months into anti-TB treatment and those samples were included (Figure 2.1). Twenty 
T2D patients (14 QFN positive and 6 QFN negative) and six healthy controls (HC) (all 
were QFN positive) were included (Figure 2.1). 
2.3  Clinical Tests 
Pulmonary TB was diagnosed in TB patients using the mycobacterial growth indicator 
tube (MGIT) (Becton Dickinson (BD), Borstel, Germany) and GeneXpert (Cepheid, 
California (United States America (USA))) tests. Latent TB infection (LTBI) was 






Figure 2.1: Classification of study participants and the downstream analyses performed. Study 
participants were classified as follows: HCs, T2D, TB and TB-T2D. Two time-points, diagnosis (Dx) and 
month 2 (M2) into anti-TB treatment, was included for TB and TB-T2D patients. The QuantiFERON 
status of T2D patients and HCs were noted for as negative (QFN -ve) and positive (QFN +ve). 
2.3.1  QuantiFERON test 
One ml of whole blood collected in Lithium Heparin (LiHep) tubes (Becton Dickinson 
(BD), Borstel, Germany) was transferred into QuantiFERON-TB Gold Plus tubes 
namely Nil, TB1, TB2 and mitogen tubes (Qiagen). The tubes were incubated at 37ºC 
in a CO2 incubator for 20 hours. After 20 hours the tubes were centrifuged at 3000 x g 
for 15 minutes. Supernatant was collected and transferred to cryotubes and stored at 
-80ºC until the QuantiFERON ELISA assay was performed.  
The QuantiFERON-TB Gold Plus ELISA (Qiagen) was done in accordance to the 




samples, standards and internal controls were run in duplicate. The plate was covered 
with foil and incubated for two hours at RT. The wells were washed six times with wash 
buffer using an automated plate washer (Bio-Rad, California (USA)). Enzyme 
substrate solution was added into each of the wells and the plate was covered with foil 
and incubated for 30 minutes at RT. After incubation, enzyme stopping solution was 
added into each of the wells and the plate was read after five minutes of adding the 
stop solution. The plate was read on the iMark Microplate reader (Bio-rad) using the 
QuantiFERON-TB Gold analysis software version 2.71. 
2.3.2  MGIT test 
A sputum sample was collected from all study participants and processed in the 
Biosafety level 3 (BSL3) laboratory. One ml of sputum was transferred to a 50ml tube 
and one ml of MycoPrep (Sigma-Aldrich, St. Louis, USA) added to the sample. It was 
then vortexed for 15 seconds and incubated at room temperature (RT) for 15 minutes. 
During incubation the samples was vortexed for five second every five minutes. 
Thereafter a phosphate (PO4) buffer was added up to the 25ml mark and the tube 
inverted until the content was thoroughly mixed. The sample was then centrifuged at 
3000 x g at 16ºC for 15 minutes, the supernatant discarded and the pellet resuspended 
in one ml of PO4 buffer.  
A lysophilized vial of BBL MGIT PANTA (Sigma-Aldrich, St. Louis, USA) antimicrobial 
agent mixture was reconstituted with 15ml of BACTEC MGIT growth supplement and 
800µl of the PANTA and 500µl of decontaminated sputum added to the MGIT tube. 
MGIT tubes were then placed in a MGIT 960 instrument (BD) until the samples flagged 
positive or for 42 days if negative. Time to positivity (TTP) was recorded for each 
sample and a TTP of less than four days was noted as contaminated and these 
participants were excluded from the study. 
2.3.3 GeneXpert 
One ml of sputum and two ml of Xpert MTB/RIF Sample Reagent (SR) (Cepheid, 
California (CA) (USA)) was added into a tube and incubated for 10 minutes at RT. The 
sample was then transferred to a GeneXpert MTB/RIF cartridge ensuring the lid was 
tightly sealed. The cartridge was then transferred to the GeneXpert Dx instrument 
(Cepheid, CA, (USA)) and tested using the GeneXpert software (GeneXpert Dx 




3.  Cytokine expression 
3.1  Sample preparation 
Whole blood of study participants was collected in nine ml serum tubes (BD, 
Germany). Blood samples were centrifuged at 2 000 x g for 10 minutes and the serum 
was collected and stored in 500μl aliquots at -80°C until cytokine analysis using the 
luminex platform (Section 3.2). 
3.2  Luminex multiplex immunoassay 
The concentrations of 41 host immune markers, which included; 1) chemokine (C-X-
C motif) ligand 9 (CXCL9/MIG), Fas and matrix metalloproteinase (MMP-9) (Cat#: 
LXSAHM-03, R&D Systems, Minneapolis, USA); 2) Apo-AI and Apo-CIII (Cat#: 
APOMAG-62K, Merck Millipore, USA); 3) C-reactive protein (CRP) and α1-antitrypsin 
(Cat#: HNDG2MAG-36K, Merck Millipore, USA); 4) complement C2, complement C4b, 
complement C5 and complement C5a (Cat#: HCMPMAG-19K, Merck Millipore, USA); 
5) soluble interleukin (sIL) 2 receptor alpha (sIL-2Rα), sIL-4 receptor (sIL-4R) and sIL-
6 receptor (sIL-6R) (Cat#: HSCRMAG-32K, Merck Millipore, USA); 6) eotaxin, 
granulocyte macrophage-colony stimulating factor (GM-CSF), G-CSF, IFN-α2, IFN-γ, 
IL-1α, IL-1β, IL-Ira, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, soluble 
interferon gamma inducible protein 10 (IP-10), macrophage-derived chemokine 
(MDC), macrophage inflammatory proteins (MIP-1α), MIP-1β, transforming growth 
factor-α (TGF-α), TNF-α, TNF-β, vascular endothelial growth factor (VEGF) (Cat#: 
HCYTOMAG-60K, Merck Millipore, USA) were measured in the serum samples (using 
the kits indicate in brackets) of the participants described above (Figure 2.1). 
The assays were conducted in accordance to the manufacturer’s instructions. Briefly, 
the beads were sonicated for 30 seconds and then vortexed for 1 minute before they 
were mixed. After adding all the beads to the mixing bottle, a set volume was added 
to each well. The plates were incubated for 2 hours at RT and some plates were 
incubated overnight on the shaker at 4°C. Detection antibody was then added into 
each of the wells and incubated for an hour on the shaker at RT. Streptavidin 
phycoerythrin was added at the end of incubation and placed on the shaker to incubate 
for 30 minutes on the shaker at RT. Washes were done on the plates on each of the 
wells at the end of every incubation. On the last wash, sheath fluid was added to each 




Bio-Rad Laboratories, Hercules, CA, USA) (supplier) and the concentration of each 
analyte determined using the Bio-Plex manager software version 6.1 (Bio-Rad 
Laboratories). 
The serum samples of kits 1-5 were diluted with serum matrix in a; 1:2, 1:4000, 1:2000, 
1:200 and 1:5 respectively and the samples in kit 6 were ran neat. All the samples, 
quality and internal controls were evaluated in duplicates. The quality and internal 
control values passed for all the kits as they were within the recommended range as 
stipulated by the manufacturer.  
4.  Phenotyping of B cells 
4.1 Whole blood lysing 
Red blood cells (RBCs) of one ml of whole blood (WB) collected in Sodium Heparin 
(NaHep) tubes (BD, Germany) were lysed by adding nine ml of fluorescence activated 
cell sorting (FACS) lysing solution containing a fixative (1:10 dilution) (BD, (USA). After 
lysing the RBCs, the cells were washed twice with phosphate buffered saline (PBS) 
(Thermo Fisher Scientific, Massachusetts, United Kingdom (UK)) and centrifuged at 
400 x g for 10 minutes. Thereafter, the cells were cryopreserved in one ml cryo 
medium consisting of 90% fetal bovine serum (FBS) (Biowest, Missouri, USA) and 
10% Dimethyl sulfoxide (DMSO) (Millipore, Billerica, MA, USA). The pellets were 
stored overnight at -80°C in Mr frosty containers containing isopropanol (Fisher 
Scientific, Loughborough, UK) and then transferred and stored at -80°C freezer. 
4.2 Thawing of Whole Blood samples 
Cells were retrieved from the -80°C freezer and placed in a 37°C water bath. Before 
the pellets were completely thawed, the cells were transferred in a dropwise manner 
into a 15ml tube containing 10ml of PBS. The cells were centrifuged at 400 x g for 10 
minutes, and the pellet washed with 10ml PBS, after which the cells were stained as 
described in section 4.4. 
4.3  Cell Stimulation 
For optimization experiments, cells were stimulated with phytohemagglutinin (PHA) 
(Bioweb, Johannesburg, South Africa). After thawing and washing of cells, cells were 
transferred to 96 well round bottom plates (Thermo Fisher Scientific, UK) and 5µg/ml 




incubator containing CO2. At the end of the stimulation, the cells were washed twice 
with PBS and centrifuged at 400 x g for 10 minutes in between wash steps. 
4.4 Cell Surface Staining of Whole Blood 
PHA stimulated cells were resuspended in FACS buffer (2% FBS in PBS), transferred 
into FACS tubes and centrifuged at 400 x g for five minutes. Cells were resuspended 
in 20μl of FACS buffer (unstained cells) or in 20µl of antibody mix containing the 
concentration of antibodies as determined in the titration experiment (section 4.5). 
Cells were incubated at 4ºC (in the dark) for 45 minutes. Cells were washed twice with 
200µl FACS buffer and centrifuged at 400 x g for five minutes. After the last wash step, 
the pellet was resuspended in 200µl FACS buffer and stored at 4ºC until acquisition 
with the 13-parameter LSR II instrument from BD equipped with BD FACS Diva 
software v8.0.1 (BD, Germany). On average, 400 000 events were acquired for each 
sample. Data obtained from the LSR II was analysed using FlowJo Version 10 
software (Treestar, San Carlos, CA) 
4.5 Titration experiment 
Prior to staining the study participant samples, antibody titrations were conducted to 
determine the optimal antibody concentration where non-specific binding of antibodies 
are minimal and a clear separation between the negative and positive cell populations 
are detected. The following markers were included in the WB FACS panel and 
therefore titrated: CD3 (T cell marker) (PerCP-Cy5.5), CD4 (T helper cell marker) 
(BV421), CD8 (Cytotoxic T cell marker) (APC-R700), CD5 (B-1a cell marker) (BV510), 
CD19 (B cell marker) (FITC), CD125/IL-5 receptor alpha (IL-5Rα) (PE), CD178 (FasL) 
(APC), IgM (PE-Cy5), CD24 (B cell activation marker) (APC-H7), CD27 (Memory B 
cell marker) (PE-CF594) and CD38 (activation marker) (BV605). All the antibodies 
were purchased from BD (BD, Germany). Each antibody was titrated with the starting 
concentration being 2-fold higher than the manufacturer’s recommended 




Figure 2. 2: Serial dilution used for FACS antibody titration experiments. The starting dilution in 
the dilution series (1:10) was 2-fold higher than the manufacturers recommended concentration for each 
antibody (1:20). From the 1:10 dilution the antibody was further diluted (1:2) by adding 30μl of the 1:10 
dilution to a tube containing 30μl of staining buffer (2%FBS in PBS). Thereafter, 30μl each tube was 
transferred to the next containing 30μl of staining buffer. This process was repeated for a total of five 
concentrations. 
During titration experiments, an unstained sample serving as a negative control was 
used to determine the position of the negative gate that should be applied to all 
samples. This gate was then used determine the optimal concentration for the 
antibody (Figure 2.3). The median fluorescent intensity (MFI) from each dilution of the 
antibody was obtained and the signal to background noise ratio calculated. The 
concentration with the highest signal to noise ratio for each antibody was selected as 





Figure 2. 3: The shifts in negative and positive cell populations at different antibody 
concentrations included in the serial dilution. The titration of CD8 (APC-R700) was used to illustrate 
the shift in negative and positive cell populations. A 2-fold dilution series was done starting from a 
dilution of 1:10 to 1:320 (from top left to bottom right). As illustrated above, the lower concentrations 
showed a clear distinction between the cell populations as observed. The histograms were obtained 
from FlowJo version 10. 
 
Figure 2. 4: Dilutions vs ratio to background noise plot. The MFIs of the negative and positive CD8 
cell population were obtained from FlowJo version 10. The background noise to signal ratio was 
measured by dividing the positive median by the negative median of the same concentration for each 
of the dilutions. In this example, the highest fluorescent intensity was detected for the 1:160 dilution, 
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4.6 Antibody compensation 
The fluorophores conjugated to antibodies can be excited by more than one laser and 
the detectors can pick up signals from different fluorophore resulting in a spill over. 
Therefore, the aim of a compensation was to detect whether there was fluorophore 
spill over in the different detection channels. Compensation was done using 
compensation beads. One hundred μl of FACS buffer was added into FACS tubes 
followed by one drop of negative and positive compensation beads (BD Biosciences). 
Antibodies were added to the relevant FACS tubes as per the selected MFI 
concentration and an unstained with positive and negative beads was used as control. 
The beads were pulse vortexed and incubated at 4ºC (in the dark) for 45 minutes. The 
beads were washed with two ml of FACS buffer and centrifuged at 200 x g for 10 
minutes. Beads were resuspended in 500μl FACS buffer and stored at 4°C (in the 
dark) until acquisition. Post-acquisition on the LSR II, the compensation was 
calculated, and a correction performed to correct for the overspill in each channel. 
4.7 Fluorescence Minus One (FMO) Experiment 
Our flow panel had eleven colours and as explained in the previous section this would 
increase the chances of background staining as a result of fluorescent spill over, 
resulting in false positive signals. The aim of an FMO experiment was to identify 
whether fluorophores spilt over into other channels and to resolve problems that may 
have not been easily detected during compensation. FMO controls are important when 
the panel measures markers with rare events as was evident in this panel. Lysed WB 
was added into 12 FACS tubes, all but one antibody was added to each tube with a 
different antibody excluded in each of the tubes. The staining protocol as stipulated in 
section 4.4 was used. Samples were acquired using the LSR II instrument and the 
data analysed using FlowJo. WB samples stimulated with PHA (5µg/ml) were stained 






4.8 Gating Strategy 
Samples were run in batches of 20 and an unstained sample was included for each 
study participant. The following gating strategies were used: a time gate was done to 
assess the quality of the run and to test if there were any disturbances during sample 
acquisition. Doublets were excluded through gating for single cells based on forward 
scatter height (FSC-H) and FSC area (FSC-A). Lymphocyte populations were selected 
based on cell size and granularity of the cells by gating on the side scatter area (SSC-
A) and FSC-A. Table 2.1 illustrates the B and T cell phenotypes that were assessed 
for this study. 
Table 2.1: The phenotypes and their characterization. 
Phenotype Characterization 
CD4+CD38+ Activated T-helper cells 
CD8+CD38+ Activated cytotoxic cells 
CD19+CD27+ Resting memory B cells 
CD19+CD24+CD27+ Activated memory B cells 
CD19+CD5+IgM+CD38+CD125+CD178+ Killer B cells 
CD19+CD5+IgM+CD38+CD125-CD178+ Killer B cells 
CD19+CD5+CD24+CD38+ Bregs 
CD19+CD24hiCD38hi Bregs 
CD19+CD24hiCD38hiCD125+CD178+ Killer Bregs 






To characterize the expression of T cells, the lymphocyte gate was used to plot for 
CD3 positive cells. T helper (CD4) and cytotoxic (CD8) T cells were plotted from CD3+ 
cells and their activated function was determined through gating for CD4+ and CD8+ 
cells that expressed CD38 respectively (Figure 2.5.1). 
 
Figure 2.5.1: The gating strategy for the characterization of activated T cells. Shown above are 
flow cytometry plots retrieved from an analysis done on FlowJo version 10. From left to right the time 
gate, single cells and lymphocytes were selected based light scatter signal. CD3+ cells (T cells) were 
selected and gated for CD4+ (T-helper cells) and CD8+ (Cytotoxic cells) and their activation function 






B cells were determined through gating on the CD3 negative cells then CD19+ for the 
identification of B cells and their apoptotic ability was investigated through the 
expression of the following phenotypes CD125-CD178+ and CD125+CD178+ (Figure 
2.5.2). In Figure 2.5.3 memory B cells a subpopulation of B cells was determined 
through using the same gating strategy for B cell identification were CD27+ cells were 
defined as resting memory B cells and CD24+CD27+ as activated memory B cells. 
Another function of B cells that was investigated was that of killer B cells which were 
defined through firstly gating on CD19+IgM+ followed by gating on CD5+CD38+ and 
killer function was determined through gating on CD125-CD178+ and CD125+CD178+ 
as shown on Figure 2.5.4. 
 
Figure 2.5.2: The gating strategy of B cells. Shown above are flow cytometry plots retrieved from an 
analysis done on FlowJo version 10. From left to right the time gate, single cells and lymphocytes were 
selected based light scatter signal. The characterization of B cells was done through gating on CD3 
negative cells and plotting on CD19+ cells. Their killer function was accessed through the expression of 






Figure 2.5.3: The gating strategy of Memory B cells. Shown above are flow cytometry plots retrieved 
from an analysis done on FlowJo version 10. From left to right the time gate, single cells and 
lymphocytes were selected based light scatter signal. CD3- cells were gated on for the characterization 







Figure 2.5.4: The gating strategy of Killer B cells. Shown above are flow cytometry plots retrieved 
from an analysis done on FlowJo version 10. From left to right the time gate, single cells and 
lymphocytes were selected based light scatter signal. CD3- cells were gated for CD19+IgM+ expression 
from where the expression of CD5+CD38+ plotted and their apoptotic ability was identified through the 





The regulatory function of B cells as defined in Table 2.1 was also investigated and 
the gating strategy shown in Figure 2.5.5. CD5+ cells were gated from the lymphocyte 
population after which CD19+ was gated on and CD24+CD38+ cells were defined as 
regulatory B cells. The final phenotype was the killer regulatory B cells (Bregs) and 
identification of B cells was done shown in Figure 2.5.2 after which CD24hiCD38hi 
defined as Bregs and their apoptosis ability defined through the expression of 
phenotype CD125-CD178+ and CD125+CD178+ cells as shown in Figure 2.5.6. 
 
 
Figure 2.5.5: The gating strategy of regulatory B cells. Shown above are flow cytometry plots 
retrieved from an analysis done on FlowJo version 10. From left to right the time gate, single cells and 
lymphocytes were selected based light scatter signal. Lymphocytes were gated for CD5+ cells and 





Figure 2.5.6: The gating strategy of killer regulatory B cells. Shown above are flow cytometry plots 
retrieved from an analysis done on FlowJo. From left to right the time gate, single cells and lymphocytes 
were selected based light scatter signal. CD3- cells were gated to plot for CD19+ cells were the 
phenotype of interest CD24hiCD38hi (Bregs) and the expression of its killer function expressed as 
CD125+CD178+ and CD125-CD178+ phenotype. 
 
5. Statistical analysis 
For the analysis of the demographic and biochemical parameters an unpaired 
Student’s t-test with a non-parametric Krusal-Wallis test with a Dunns post hoc was 
done using GraphPad prism software version 6 (San Diego, California, USA), The 
luminex and whole blood flow cytometry data were analyzed using Statistica version 
13.4 (StatSoft, Tulsa, Oklahoma, USA). An analysis of variance (ANOVA) with a Fisher 
LSD post hoc test was used to measure difference among the four patient groups. The 
luminex and whole blood flow cytometry results were represented as LS means with 
95% confidence intervals (CI). A P-value <0.05 indicated statistical significance 
difference and a P ≥0.05 – 0.09. indicates a trend. Qlucore Omics Explorer 3.5 





3. Cytokine expression study 
Patients with T2D have chronic low-grade inflammation and an increase in pro-
inflammatory cytokines. TB patients with T2D have dysregulated immune responses 
(Podell et al., 2014), resulting in these patients presenting with a greater extend of 
disease. The aim of this study was therefore to further investigate the immunological 
imbalance in serum protein levels in individuals with and without TB and T2D, by 
including a larger number of serum analytes, to better characterize the differences 
observed in these individuals. Serum samples were collected from HC (n=9), patients 
with T2D (n=11), TB (n=25) and TB-T2D (n=3) before TB treatment and from patients 
with TB (n=9) and TB-T2D (n=2) at month two of TB treatment. The serum 
concentrations of 32 markers were determined using the luminex multiplex 
immunoassay technology. 
3.1 Demographics and clinical characteristics of study participants 
Majority of the study participants are females (Table 3.1) except for the TB group that 
had mostly males. T2D patients have the highest body mass index (BMI) and 
individuals with a BMI >30Kg/m2 are defined as obese (WHO), characterizing the T2D 
patients in this study as obese (Table 3.1). Since BMI will influence cytokine 
responses, we therefore statistical corrected for BMI and found that the results did not 
change after correcting for BMI. HbA1c and lipid concentrations were measured in 
HCs and patients with T2D, in TB-T2D patients at baseline (BL), HbA1c levels were 
measured before the patients underwent anti-TB treatment. As expected, the HbA1c 





Table 3. 1: The demographics and clinical characteristics of HC, T2D, TB and 
TB-T2D patients. 




     












Age (years):      
Baseline 













     













HbA1c (%) 5.31±0.38a 10.05±2.45b - 13.77±5.32b <0.0001 
LDL (mmol/L) 2.44±0.74 2.69±1.00 - - 0.67 
HDL (mmol/L) 1.48±0.43 1.42±0.43 - - 0.87 
Triglycerides (mg/dL) 1.62±0.83 1.86±0.98 - - 0.56 
Total cholesterol 
(mg/dL) 
4.66±0.90 4.95±1.19 - - 0.66 
*The values are expressed as mean ± standard deviation. The study participants consisted of HC (n=9), 
T2D (n=11), TB (n=25) and TB-T2D (n=2) and patients with TB followed up two months into their anti-
TB treatment; TB (n=9) and TB-T2D (n=2). The statistical analysis was done using a Mann-Whitney U 
test to compare two groups and a one-way analysis of variance (ANOVA) with a Bonforoni post hoc for 
comparing more than two groups. Letters a and b indicate statistical significance. 
 
3.2 Cytokine profile differs between patient groups. 
The concentration of 32 serum analytes were measured in HCs T2D, TB and TB-T2D 
patients using the Luminex platform. Unbiased hierarchical clustering of the mean 
concentration of each analyte in each patient group was done and a heatmap 
generated using the Qlucore omics explorer software. Eight cytokine clusters were 
observed (Figure 3.1). Concentrations of MDC, G-CSF, MIP-1b, MMP-3, IL-2, Fas, IL-
13, CXCL9/MIG and IL-1β (cluster 1) are higher in HCs compared to the other groups. 
The concentrations of C4 and complement C4b decrease in the presence of TB 
(cluster 2). Concentrations of complement C5, C2, C5a and sIL-4R (cluster 3) and sIL-






Concentrations of MIP-1α, IL-10 and GCP-2 are higher in T2D patients compared to 
other groups (cluster 4). T2D patients have low IFN-γ concentrations (cluster 6) while 
IL-12p40 and eotaxin concentrations are higher in HCs and TB-T2D patients. Mtb 
promotes an increased expression of the serum analytes in cluster 7 (Apo AI, Apo CIII, 
α1-antitrypsin, IL-2Ra and IP-10) and cluster 8 (SAA, VEGF and CRP). However, the 
serum markers associated with cluster 7 are mainly higher in TB patients. No statistical 
significance was found on the concentration of serum analytes in cluster 2 and hence 
their data will not be shown in the sections to follow.  
 
Figure 3.1: Differential expression of 32 serum cytokine concentrations at baseline in the four 
patient groups. The serum concentrations of 32 analytes were determined in HCs (n=9), T2D (n=11), 
TB (n=25) and TB-T2D (n=3) patients at BL. There are 8 distinguishable clusters based on the mean 
concentrations of the serum markers. The colour blue denotes low concentrations of serum markers 
while the colour red denotes high concentrations of serum markers as shown on the key on the left of 





3.3 Serum concentrations of CXCL9/MIG, IL-2, MDC, MIP-1b and MMP-3 are 
higher in HCs 
In the periphery, the concentration of proteins listed in cluster 1 is higher in HCs (Figure 
3.2). Cluster 1 includes cytokines, chemokines and a protease which are all associated 
with inflammatory responses, cell recruitment, cell damage and cell survival pathways. 
CXCL9/MIG, IL-2 and MMP-3 are significantly higher in HCs compared to T2D and TB 
patients. MDC and MIP-1β was significantly higher in HCs compared to TB patients 
and there was a trend for it to be higher in HCs compared to patients with T2D (p=0.05 
and p=0.06, respectively). No significant differences were seen in the other analytes 






Figure 3.2: Circulating serum concentrations of cytokines included in cluster 1. The mean serum 
concentrations of CXCL9/MIG (A), IL-2 (B), MDC (C), MIP-1b (D) and MMP-3 (E) were measured in 
HC (n=9) and patients with T2D (n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis was done 
using a one-way analysis of variance (ANOVA) with a Fisher LSD post hoc test to compare the 
differences among groups. Results are represented as LS means with 95% confidence intervals. 
Significant letters are used to indicate significant differences. Groups sharing letter are not significant 









3.4 The serum concentration of sIL-4R and complement C5a is lower in 
patients with T2D and TB-T2D. 
The complement system consists of proteins with proteolytic properties and upon 
activation, they induce cell lysis, opsonisation of pathogens and the activation of 
inflammatory pathways, in efforts to combat and enhance clearance of an invading 
pathogen. The protein concentration of the C5a in the serum is significantly lower in 
patients with TB-T2D compared to HCs and TB patients (Figure 3.3). There was a 
trend for protein concentrations of sIL-4R to be lower in T2D patients (p=0.06) and TB-
T2D patients (p=0.09) compared to HCs. No significant differences were found on 
analytes C5 and C2 included in this cluster (data not shown).  
 
 
Figure 3.3: Serum concentrations of sIL-4R and complement C5a from which forms part of 
cytokine cluster 3. The mean serum concentrations of sIL-4R (A) and complement C5a (B) were 
measured in HCs (n=9) and patients with T2D (n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis 
was done using a one-way analysis of variance (ANOVA) with a Fisher LSD post hoc test to compare 
the differences between groups. Results are represented as LS means with 95% confidence intervals. 
Significant letters are used to indicate significant differences. Groups sharing letter are not significant 






3.5 The serum concentration of IL-10 is higher in patients with T2D. 
IL-10 is produced by immune cells such as; T cells, NK cells and APCs. IL-10 can 
inhibit MHC class II and co-stimulatory molecule expression restricting the migration 
of pro-inflammatory cytokines and chemokines to lymph node leading to the failure of 
the recruitment of immune cells to the site of infection (Couper et al., 2008). In T2D 
patients, the concentration of IL-10 is highest in the T2D group with significance only 
reached when compared to the TB (Figure 3.4). No significant differences were found 
on analytes MIP-1α and GCP-2 included in this cluster (data not shown). 
 
Figure 3.4: The serum concentrations of IL-10 in HCs and patients with T2D, TB and TB-T2D 
(cluster 4).The mean serum concentration of IL-10 was measured in HCs (n=9) and patients with T2D 
(n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis was done using a one-way analysis of 
variance (ANOVA) with a Fisher LSD post hoc test to compare the differences amongst groups. Results 
are represented as LS means with 95% confidence intervals. Significant letters are used to indicate 
significant difference. Groups sharing letter are not significant difference from each other. The 





3.6 The concentrations of sIL-6R and sVEGR3 are higher in patients with 
TB-T2D. 
The serum cytokine concentrations in cluster 5 (Figure 3.1) are higher in TB-T2D 
patients. The binding of IL-6 to the membrane bound IL-6R modulates inflammatory 
responses through activating the JAK-STAT pathway (Hurst et al., 2001). In the 
absence of IL-6R, sIL-6R/IL-6 can activate trans-signalling in cells (Chakraborty et al., 
2011).The serum concentration of sIL-6R is significantly higher in TB-T2D patients 
compared to HCs and TB patients (Figure 3.5A). VEFG are contributory proteins in 
the lymphatic vascular system during angiogenesis and binds to the VEFG receptor 
(VEGFR) (Debrah et al., 2006). The soluble VEGFR3 concentration is significantly 
higher in TB-T2D patients in comparison to all the other groups (Figure 3.5 B). No 
significant differences were found on the cytokine concentration of IL-5 included in this 
cluster (data not shown). 
 
 Figure 3.5: Serum concentrations of sIL-6R and sVEFGR3 in HCs and patients with T2D, TB and 
TB-T2D (cluster 5). The mean serum concentrations were measured in HCs (n=9) and patients with 
T2D (n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis was done using a one-way analysis of 
variance (ANOVA) with a Fisher LSD post hoc test to compare the differences between groups. Results 
are represented as LS means with 95% confidence intervals. Significant letters are used to indicate 
significant difference among groups. Groups sharing letter are not significant difference from each other. 









3.7 The serum concentrations of Eotaxin is lower in T2D and TB patients. 
Eotaxin, a chemokine facilitating the movement of eosinophils, is significantly lower in 
patients with T2D and TB compared to HCs and there is a trend for it to be lower in 
TB-T2D patients (p=0.08) (Figure 3.6). No significant differences were found on 
cytokines IL-12p40 and IFN-γ included in this cluster (data not shown). 
 
Figure 3.6: The serum concentrations of Eotaxin in HCs and patients with T2D, TB and TB-T2D 
(cluster 6). The mean serum concentrations of eotaxin were measured in HCs (n=9) and patients with 
T2D (n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis was done using a one-way analysis of 
variance (ANOVA) with a Fisher LSD post hoc test to compare the differences among groups. 
Significant letters are used to indicate significant difference among groups. Results are represented as 
LS means with 95% confidence intervals. Groups sharing letter are not significant difference from each 
other. The concentration of Eotaxin is represented as pg/ml. 
3.8  Serum concentrations of cytokines in cluster 7 are higher in TB 
patients. 
The serum cytokines in cluster 7 (Figure 3.1) consists of apolipoproproteins (apo) 
which form covalent bonds with lipids to form lipoproteins. By doing so they are 
responsible for the regulation and transportation of lipids to different cells in different 
tissues (Mahley et al., 1984). The serum concentration of Apo AI is significantly higher 
in TB patients compared to HCs and patients with T2D (Figure 3.7A). It is also higher 
in TB patients compared to TB-T2D patients, however, it did not reach statistical 
significance. Apo CIII was significantly higher in TB patients compared to all other 
groups (Figure 3.7B).  
Alpha1-antitrypsin (α1-antitrypsin) is a protease inhibitor responsible for the 




The degradation of α1-antitrypsin induces inflammation (Hunt and Tuder, 2012). sIL-
2Rα is cleaved from the cell membrane through enzymatic processes and competes 
with the IL-2R for IL-2 resulting in the down regulation of IL-2 mediated immune 
response (Vanmaris and Rijkers, 2017). Concentrations of both, a1-antitrypsin and 
sIL-2Rα, are significantly higher in TB patients compared to HCs patients with T2D. 
No significant differences in the serum concentration of cytokine IP-10 included in this 
cluster (data not shown). 
 
Figure 3.7: The serum concentrations of Apo AI, Apo CIII, α1-antitrypsin and sIL-2Rα in HCs and 
patients with T2D, TB and TB-T2D (cluster 7). The mean serum cytokine concentrations were 
measured in HCs (n=9) and patients with T2D (n=11), TB (n=25) and TB-T2D (n=3). Statistical analysis 
was done using a one-way analysis of variance (ANOVA) with a Fisher LSD post hoc test to compare 
the differences between groups. Results are represented as LS means with 95% confidence intervals. 
Significant letters are used to indicate significant difference among groups. Groups sharing letter are 
not significant difference from each other. The concentrations of Apo AI, Apo CIII, α1-Antitrypsin are 





3.9  The serum concentrations of CRP, SAA and VEGF are higher in TB and 
TB-T2D patients. 
The inflammatory marker C-reactive protein (CRP) is significantly higher in TB and 
TB-T2D patients than in HCs and T2D patients (Figure 3.8A). SAA is significantly 
higher in TB patients in comparison to patients with T2D (Figure 3.8B). VEGF 
concentrations are significantly higher in TB patients compared to HCs and patients 
with T2D. There is also a TB-T2D patients have higher concentrations than patients 
with only T2D (Figure 3.8C). 
 
Figure 3.8: The serum concentrations of CRP, SAA, and VEGF in HC, T2D, TB and TB-T2D 
participants of cluster 8 derived from a heatmap in Figure 3.1. The mean serum cytokine 
concentrations were measured in HCs (n=9) and patients with T2D (n=11), TB (n=25) and TB-T2D 
(n=3). Statistical analysis was done using a one-way analysis of variance (ANOVA) with a Fisher LSD 
post hoc test to compare the differences between groups. Results are represented as LS means with 
95% confidence intervals. Significant letters are used to indicate significant difference among groups. 
Groups sharing letter are not significant difference from each other. The concentrations of CRP and 







3.10  The cytokine profile of differs between TB and TB-T2D patients in 
response to anti-TB treatment.  
The mean concentration of 32 serum analytes were measured in serum samples of 
TB and TB-T2D patients before initiation of anti-TB treatment and two months into 
anti-TB treatment. Using the Qlucore Omix explorer software we performed an 
unbiased hierarchical clustering of the mean concentration of the 32 markers and 
found five distinguishable clusters (Figure 3.9). The serum concentrations of CRP, IP-
10, C4, Complement C4b, α1-antitrypsin, sIL-2Ra, Complement C5a, Apo AI, Apo CIII, 
IL-13 decrease two months into anti-TB treatment in TB-T2D patients while the 
concentration levels differ in TB patients at this time-point (cluster 1).  
The serum concentrations of SAA and VEGF decrease in TB and TB-T2D in response 
to anti-TB treatment (cluster 2). There is no treatment response in the serum 
concentration of analytes in cluster 3 (Figure 3.8). The serum concentrations of 
sVEGFR3, sIL-6R, G-CSF, IL-1β, IL-5 and IFN-γ decrease in TB-T2D patients in 
response to anti-TB treatment at month 2. The opposite effect is true for the serum 
analytes of cluster 5 (Figure 3.8) as their serum concentrations increase in response 
to treatment. No statistical significance was found on the concentration of serum 






Figure 3.9: Differential expression of 32 serum cytokine concentrations at baseline in the four 
patient groups. The serum concentrations of 32 analytes were determined in TB BL (n=25), TB-T2D 
BL (n=3), TB Month 2 (n=9) and TB-T2D Month 2 (n=2) patients at BL. There are 5 distinguishable 
clusters based on the mean concentrations of the serum markers. The colour blue denotes low 
concentrations of serum markers while the colour red denotes high concentrations of serum markers 
as shown on the key on the left of the heatmap.  The heatmap was generated using the Qlucore Omics 
explorer software Version 3.5 software. 
3.11 Serum concentrations of Apo AI, Apo CIII, α1-Antitrypsin, CRP 
 and C5a in cluster 1 change during the first two months of anti-TB 
 treatment in TB patients. 
The serum concentrations of Apo AI, Apo CIII, α1-antitrypsin and CRP significantly 
decrease from baseline to month 2 in TB patients, but not TB-T2D (Figure 3.10 A-D). 
Apo CIII and C5a concentrations are significantly lower in TB-T2D patients compared 
to TB patients at baseline (Figure 3.10 B and E). No significant differences were found 






Figure 3.10: The serum concentrations of Apo AI, Apo CIII, α1-antitrypsin, CRP and complement 
C5a (A-E) at baseline and two months into anti-TB treatment, cluster 1 derived from a heatmap 
in Figure 3.9). The mean concentration for TB (n=25) and TB-T2D (n=3) at baseline and TB (n=9) and 
TB-T2D (n=2) patients, month 2 into TB treatment. Statistical analysis was done using a one-way 
analysis of variance (ANOVA) with a Fisher LSD post hoc test to compare the differences between 
groups. Results are represented as LS means with 95% confidence intervals. Significant letters are 
used to indicate significant difference among groups. Groups sharing letter are not significant difference 
from each other. The serum concentrations of Apo AI, Apo CIII, α1-antitrypsin and CRP were 







3.12 The serum concentrations of VEGF decrease in TB and TB-T2D 
patients in response to treatment 
On the heatmap in Figure 3.9 VEGF is part of cluster 2 and based on the cluster the 
concentrations are higher before TB and TB-T2D patients undergo treatment and 
decrease two months into treatment (Figure 3.11). There is only statistically 
significance in TB patients. No significant differences were found on SAA included in 
this cluster (data not shown). 
 
 
Figure 3.11: The serum concentration VEGF at baseline and two months into anti-TB treatment, 
cluster 2 derived from a heatmap in Figure 3.9).VEGF concentrations were measured in TB (n=25) 
and TB-T2D (n=3) at baseline and TB (n=9) and TB-T2D (n=2) patients two months into anti-TB 
treatment. Statistical analysis was done using a one-way analysis of variance (ANOVA) with a Fisher 
LSD post hoc test to compare the differences between groups. Results are represented as LS means 
with 95% confidence intervals. Significant letters are used to indicate significant difference among 
groups. Groups sharing letter are not significant difference from each other. The serum concentration 





3.13  The serum concentrations of the analytes included in cluster 4 
are higher in patients with TB-T2D compared to TB patients at baseline. 
At the initiation of TB treatment, sVEGFR3 and sIL-6R concentrations are higher in 
patients with TB-T2D compared to patients with TB (Figure 3.12 A and B). During the 
first two months of TB treatment, sIL-6R levels decrease in the TB-T2D group to levels 
similar to those observed in TB patients. sIL-6R levels remain unchanged, during this 
period, in patients with TB. No significant differences were observed in IL-5 and IL-1β 
concentrations (Figure 3.12 C and D). There are however trends suggesting IL-1β 
concentrations are higher in TB-T2D patients at baseline (p=0.09) and month 2 
(p=0.07) compared to TB patients. The trends indicate that are higher IL-1β 
concentrations in TB-T2D patients before anti-TB treatment. No significant differences 








Figure 3.12: The serum concentrations of sVEGFR3, sIL-6R, IL-5 and IL-1β (A-D) at baseline and 
two months into anti-TB treatment, cluster 4 derived from a heatmap in Figure 3.9).The mean 
concentration of TB (n=25) and TB-T2D (n=3) at baseline and TB (n=9) and TB-T2D (n=2) patients two 
months into anti-TB treatment. Statistical analysis was done using a one-way analysis of variance 
(ANOVA) with a Fisher LSD post hoc test to compare the differences between groups. Results are 
represented as LS means with 95% confidence intervals. Significant letters are used to indicate 
significant difference among groups. Groups sharing letter are not significant difference from each other. 







3.14 The serum concentrations of CXCL9/MIG, Eotaxin, MIP-1β and 
 MMP-3 are higher in TB-T2D patients at month two of TB 
 treatment. 
The serum concentrations of CXCL9/MIG, MIP-1β and MMP-3 change significantly 
over time in the TB-T2D group, but not in the TB group (Figure 3.13). There is no 
significant difference in Eotaxin concentrations in the TB-T2D group (Figure 3.13 B), 
however, a similar trend in response is observed as the latter mentioned serum 
analytes. The increase in the cytokine and chemokine concentrations is an indication 
of a treatment response in the TB-T2D group. There were no significant differences 
observed in the TB group during treatment. No significant differences were found in 
the concentration of MDC, IL-2, IL-10, Fas and IL-12p40 included in this cluster (data 
not shown). 
 
Figure 3.13: The serum concentrations of CXCL9/MIG, Eotaxin, MIP-1β and MMP-3 (A-D) at 
baseline and two months into anti-TB treatment, cluster 5 derived from a heatmap in Figure 
3.9).The mean concentration of TB (n=25) and TB-T2D (n=3) at baseline and TB (n=9) and TB-T2D 
(n=2) patients two months into anti-TB treatment. Statistical analysis was done using a one-way 
analysis of variance (ANOVA) with a Fisher LSD post hoc test to compare the differences between 
groups. Results are represented as LS means with 95% confidence intervals. Significant letters are 
used to indicate significant difference among groups. Groups sharing letter are not significant difference 
from each other. The serum concentrations of CXCL9/MIG, Eotaxin, MIP-1β and MMP-3 were 







3.15  Serum proteins correlate with lipid concentrations in HCs with 
 and without T2D. 
We have shown that dyslipidaemia in different ethnic groups are driven by different 
lipids (Restrepo et al., 2018). Although, we did not observe significant differences in 
lipid concentration of HC and T2D patient. Patients with T2D still had higher LDL, 
triglycerides and cholesterol therefore we were interested to investigate if the serum 
markers correlated with the lipid concentrations. The serum concentrations of Apo CIII 
and α1-antitrypsin are negatively correlated with triglyceride concentrations (Figure 
3.14 A and B). sIL-6R concentrations are positively correlated to LDL and cholesterol 
concentrations (Figure 3.14 C and D). There is also a negative correlation between IL-






Figure 3.14: Correlations between serum concentration analytes and periphery lipid 
concentration between the HC and T2D groups. The correlation denotes the relationship between 
the serum lipid and protein concentrations in the HCs (n=9) and patients with T2D (n=11). Significant 
correlations were observed in (A) Apo CIII and Triglycerides, (B) α1-antitrypsin and Triglycerides, (C) 
sIL-6R and LDL (D) sIL-6R and Total cholesterol and (E) sIL-6R and HDL. Black dots represent HC 










We have identified interesting clusters of cytokines and host serum immune markers 
even though some of them are not significantly different, this will aid in identifying 
pathways in which the clusters are involved. This will help us understand why T2D 
patients are more susceptible and why TB patients with T2D present have a greater 
extent of disease. It is worth noting our results are limited a small sample size 
especially in the TB-T2D group and we did not investigate the extent of disease in 
these participants.  
There was no statistical differences in lipid concentrations, they however did correlate 
with serum cytokine concentrations. Our correlation analysis did not statistical 
differentiate between the two study groups (HC and T2D), so our correlations are 
reported as an overall correlation. Investigating the immunological pathways in which 
the different clusters of cytokines are involved in could aid in understanding which 
pathways are involved in the disease progression in TB and TB-T2D patients. If 
different pathways are involved one could then speculate that it might play a role in 
susceptibility and in the extent of disease. We have not looked into their chest x-rays 
and we did not follow the patients until the end of treatment hence we can only 






4.  Phenotyping the Whole Blood of TB patients with or without T2D 
The frequencies and function of immune cells in TB patients with T2D are altered 
(Lönnroth et al., 2010; Raposo-García et al., 2017) leaving them vulnerable to 
increased Mtb replication and increased severity of TB disease. Currently, majority of 
the research investigates the immunological aspects of TB patients with T2D in 
relation to their role in T-cells and macrophages. Preliminary data obtained from our 
group should that TB patients with T2D have increased absolute B cells in comparison 
to TB patients without T2D. The role of B cells as contributors of adaptive immunity in 
TB-T2D remains largely understudied. Therefore, the aim of this chapter is to 
determine the frequency of regulatory and killer B cells by investigating the expression 
of FasL (CD178+) and IL-5Rα (CD125+) with the use of flow cytometry. For this study, 
54 whole blood samples were collected from HCs (n=6), patients with T2D (n=19), TB 
(n=14) and TB-T2D (n=3) before treatment and patients with TB (n=12) at months two 
of anti-TB treatment. 
4.1  Demographics and clinical characteristics of study participants 
Fifty-four participants were enrolled across all four patient groups for the phenotypic 
analysis of B cell. Patients with T2D are obese and TB patients are underweight at the 
initiation of treatment (Table 4.1). As highlighted in chapter 3 section 3.1, BMI was 
corrected for and no statistical differences were observed. Patients with T2D have a 
higher HbA1c. There was no statistically significant difference in lipid concentrations 
between HC and T2D groups expect for higher concentrations in the T2D group. The 





Table 4 1: Demographics and clinical characteristics of HCs, T2D patients and 
TB patients with and without T2D. 
 HC T2D TB TB-T2D P value 
Study  
Demographics 
     












Age (years):      
Baseline 













     












HbA1c (%) 5.27±0.44a 10.02±2.02b - 12.83±6.10b 0.0008 
LDL (mmol/L) 2.50±0.78 2.75±0.78 - - 0.46 
HDL (mmol/L) 1.72±0.23 1.26±0.36 - - 0.01 
Triglycerides 
(mg/dL) 
1.23±0.35 2.05±1.31 - - 0.10 
Total cholesterol 
(mg/dL) 
4.77±0.72 4.94±0.94 - - 0.52 
*The values are expressed as mean ± standard deviation. P-value <0.05 was considered as significant 
and the statistical analysis was using a Mann-Whitney U test for the comparison of two groups and a 
one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc for the comparison of more 
than two groups. Letters a-c indicate statistical significance. HbA1c (Glycated haemoglobin), HDL (High 
density lipoprotein) and LDL (Low density lipoprotein). 
4.2  CD4+ and CD8+ T cell frequencies in the different patient groups. 
CD3+ T cells were gated from the lymphocytic population and CD4+ and CD8+ T cells 
were gated from CD3+ T cells. An increased frequency of CD3+ T cells is present in 
the HCs compared to TB patients and T2D patients compared to TB patients (p=0.08), 
however these differences did not reach statistical significance (Figure 4.1A). 
Subsequently the distribution of activated (CD38+) and nonactivated (CD38-) CD4+ 
and CD8+ T cell subsets were examined. As expected, a greater frequency of CD4+ 
vs CD8+ T cells were observed in all four study groups. The frequency of CD4+ T cells 
is however the highest in patients with TB-T2D and the CD8+ T frequency lowest in 
HCs (Figure 4.1B). The percentage of activated CD4+ and CD8+ T cells are higher 




Figure 4.1: The distribution and frequencies of CD4+ and CD8+ T cells in HCs and patients with 
T2D, TB and TB-T2D prior to initiation of anti-TB treatment. A) A lymphocyte gate was used to gate 
for CD3+ T cells in WB samples. The mean frequency of CD3+ T cells are represented in (%). B) Four 
pie charts illustrate the distribution of CD3+, CD4+ and CD8+ T cells as well as activated T cells 
expressing CD38 frequencies (%) in HC (n=6), T2D (n=19), TB (n=14) and TB-T2D (n=3) before anti-
TB treatment. Pie charts were constructed on Graphpad Prism version 8. Statistical analysis was done 
using ANOVA with a Fisher LSD post hoc test to compare the differences amongst groups. Results are 
represented as LS means with 95% confidence intervals. Significant letters are used to indicate 







4.3  The frequency of memory B cells is lower in TB patients before 
initiation of anti-TB treatment 
In chapter 1 we highlighted the contribution of B cells in TB immunity as through 
cytokine production, presentation of Mtb antigens to naïve T cells and their production 
of antibodies. Joosten et al showed B cell subset frequencies were altered during TB 
disease and we want to investigate them in presence of T2D. One of the investigated 
subsets was memory B cells and they have a highly regulated memory immune cells 
are an important aspect of the immune system, providing a rapid and effective immune 
response upon a re-encounter with a specific antigen. We investigated the frequency 
of resting memory B cells and their activation state in the four patient groups. T2D 
patients have a higher frequency of resting memory B cells (CD19+CD27+) while TB 
patients have the lowest frequency (Figure 4.2B). T2D and TB patients have a lower 
percentage of activated memory B cells compared to HCs and TB-T2D patients 
(Figure 4.2A). HCs (p=0.09) and patients with T2D (p=0.09) have a higher frequency 





Figure 4.2: The distribution and frequencies of resting and activated memory B cells in the four different 
patient groups before initiation of anti-TB treatment. A) Pie charts B) Line graphs the frequencies (%) of 
resting memory B cells CD19+CD27+ and activated memory B cells CD19+CD24+CD27+ in HCs (n=6) and 
patients with T2D (n=19), TB (n=14) and TB-T2D (n=3) before initiation of anti-TB treatment. A lymphocyte, 
gated CD3- cells and CD19+ from the negative gate. Pie charts were constructed on Graphpad Prism version 
8. Statistical analysis was done using ANOVA with a Fisher LSD post hoc test to compare the differences 
amongst groups. Results are represented as LS means with 95% confidence intervals. Significant letters are 
used to indicate significant difference among groups. Groups sharing letter are not significant difference from 
each other. 
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51.94%  Resting memory B cells
48.06%  Activated memory B cells
T2D
62.89%  Resting memory B cells
37.11%  Activated memory B cells
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39.15%  Activated memory B cells
TB-T2D BL
48.41%  Resting memory B cells









4.4  Naïve B cells of TB patients have an increased expression of apoptotic 
inducers IL-5Rα and FasL 
The Fas/FasL (CD178) pathway induces cell death and the surface expression of IL-
5Rα (CD125) enhances the induction of apoptosis through the Fas/FasL pathway 
(Klinker et al., 2013). CD125 and CD178 are expressed by all immune cells. Our group 
identified that the expression of FasL and IL-5Rα was upregulated in B cells at the end 
of TB treatment (van Rensburg et al., 2016). Naїve B cell frequencies are higher in 
TB-T2D patients compared to TB patients (Figure 4.3A). Although not statistically 
significant, it is in line with what we found in absolute B cell numbers in these patients 
(manuscript in preparation).There are, however, no significant differences in B cells 
expressing CD178 in the absence of CD125 in all four study groups (CD19+CD125-
CD178+; Figure 4.3B).TB patients have a significantly higher frequency of B cells 
expressing both the apoptotic inducers CD125 (IL-5Rα) and CD178 (FasL) when 





Figure 4.3: The frequencies of B cells expressing CD125+ and CD178+. Line graphs - A) Naïve B 
cells, B) Naïve B cells expressing CD125- and CD178+ and C) Naïve B cells expressing CD125+ and 
CD178+: in HCs and patients with T2D, TB and TB-T2D before anti-TB treatment. The CD19+ gate was 
obtained from gating on the CD3- population of the lymphocyte population. Cell frequency is expressed 
in (%). Statistical analysis was done using ANOVA with a Fisher LSD post hoc test to compare the 
differences amongst groups. Results are represented as LS means with 95% confidence intervals. 
Significant letters are used to indicate significant difference among groups. Groups sharing letter are 







4.5  The expression of Killer B cells is higher in TB patients compared to 
HCs 
Killer B cells are defined by the phenotype CD19+CD5+IgM+CD38+CD125-CD178+ and 
CD19+CD5+IgM+CD38+CD125+CD178+ and their killer function defined through the 
expression of CD125-CD178+ or CD125+CD178+ specifically. The expression of killer 
B cells is phenotype specific (Figure 4.4 A and B). In the absence of CD125- (Figure 
4.5A) the expression of the killer B cells does not change within the four study groups. 
In the presence of both apoptotic markers (Figure 4.4B) the killer B cells decreases in 
patients with T2D. 
 
Figure 4.4: The frequencies of Killer B cells in HC, T2D, TB and TB-T2D at the initiation of TB 
treatment. The phenotype of killer B cells is defined by CD19+CD5+IgM+CD38+CD125-CD178+ and 
CD19+CD5+IgM+CD38+CD125+CD178+ and the d frequencies (%) in HC (n=6), T2D (n=19), TB (n=14) 
and TB-T2D (n=3) before anti-TB treatment. The CD19+ gate was obtained from gating on the CD3- 
population of the lymphocyte population. Statistical analysis was done using ANOVA with a Fisher LSD 
post hoc test to compare the differences between groups. Results are represented as LS means with 
95% confidence intervals. Significant letters are used to indicate significant difference among groups. 
Groups sharing letter are not significant difference from each other. 
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4.6 The expression of regulatory B cells is higher in TB patients at baseline 
and lower in patients with T2D 
Regulatory immune cells are associated with an immunosuppressive function through 
the secretion of anti-inflammatory cytokines IL-10, TNF-β and IL-35 responsible for 
immune tolerance proving to be beneficial to the host, however in the presence of 
disease this function is altered (Medzhitov, 2008; Vered et al., 2013). To better 
understand the regulatory role of B cells in TB patients with and without T2D, we 
investigated the different Breg phenotypes as defined by Blair et al. whose mechanism 
was assessed through their effect on autoimmune disease. Increased frequencies of 
CD19+CD5+CD24hiCD38hi Bregs are found in TB patients (Figure 4.4B) compared to 
T2D (p=0.08). The expression of Bregs at the initiation of treatments response seems 
to be driven by TB where their frequencies are increased in relation to patients with 
T2D (T2D and TB-T2D patients). Although no statistical significance was observed in 





Figure 4.5: The frequencies of Regulatory B cells in HCs and T2D, TB and TB-T2D patients at the 
initiation of TB treatment. The frequencies (%) of Bregs; CD19+CD5+CD24+CD38+ and 
CD19+CD5+CD24hiCD38hi were measured in HCs (n=6) and T2D (n=19), TB (n=14) and TB-T2D (n=3) 
patients before anti-TB treatment. The CD19+ gate was obtained from gating on the CD3- population of 
the lymphocyte population. Statistical analysis was done using Statistica using an ANOVA with a Fisher 
LSD post hoc test to compare the differences among groups. Results are represented as LS means 
with 95% confidence intervals. Significant letters are used to indicate significant difference. Groups 
sharing letter are not significant difference from each other. 
4.7 The frequency of B cells and Bregs expressing apoptotic markers 
CD125 and CD178 change during the first two months into anti-TB 
treatment 
Sputum smear conversion of TB patients undergoing anti-TB treatment commonly 
occurs at two months of treatment (Azarkar et al., 2016). The two-month sputum 
smear conversion is a useful predictor of anti-TB treatment outcomes (Kuaban et al., 
2009; Singla et al., 2003) and delay in sputum smear conversion is associated with 
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conversion (Socorro Nantua Evangelista et al., 2018). We therefore investigated B cell 
frequencies in TB patients before and at months two of anti-TB treatment. B cells 
expressing apoptotic markers (CD19+CD125+CD178+) decrease by two months of 
treatment (p=0.07) (Figure 4.6A). the frequency of Killer B cells, on the other hand 
(CD5+CD19+CD38+IgM+CD125-CD178+) increase from baseline to month to of anti-
TB treatment (Figure 4.6B). 
 
Figure 4.6: The frequency of B cells expressing CD125+ and CD178+ and 
CD19+CD5+IgM+CD38+CD125-CD178+ at the initiation and month two into anti-TB treatment. (A) 
The frequency (%) of B cells expressing CD125+ and CD178+ (p=0.07) and (B) the frequency (%) of 
killer B cells is defined by CD19+CD5+IgM+CD38+CD125-CD178+ (p=0.05) TB (n=14) at baseline and 
TB (n=12) two months into anti-TB treatment. Statistical analysis was done using ANOVA with a Fisher 
LSD post hoc test to compare the differences between groups. Results are represented as LS means 
with 95% confidence intervals. Significant letters are used to indicate significant difference among 







There is a decline in T-cell specific immune responses in Mtb infected individuals, 
demonstrated by the decline in functional T cells in these patients in comparison to HCs. 
Interestingly, TB-T2D patients were observed to have slightly lower activated T-cell 
frequencies compared to TB patients, suggesting an augmented immune cell 
dysfunction associated with T2D. The low memory B cell frequencies in TB patients are 
suggestive of a dysfunctional memory B cell response compared to the memory immune 
response of HCs and T2D patients. Naїve B cells expressing apoptotic markers CD125+ 
and CD178+ decrease two months into anti-TB treatment while the phenotypic killer B 
cells increase at month two. There were no statistically significant differences between 






5.1 Cytokine profile of TB patients with and without T2D 
Patients with T2D infected with Mtb are at an increased risk of developing TB and 
when they develop TB, they present with a greater severity to the disease. The 
immunological mechanisms driving the increased susceptibility are still largely 
unknown and there is still a need to further characterize the immune responses in 
these patients to better understand the cause for the increased susceptibility. The 
increased susceptibility is suspected to be due to the defects in the phagocytic ability 
of monocytes in patients with T2D. Phagocytosis is heavily dependent on 
opsonization, opsonins bind to the surface of the pathogen, increasing the number of 
binding sites that the phagocytic receptors can bind to, enhancing the efficiency of 
phagocytic cells. In patients with T2D, the functional efficacy of opsonin receptors 
namely FcγR and the complement receptor expressed on phagocytic cells such 
macrophages, neutrophils and DCs is altered (Restrepo et al., 2014). There is also a 
delay in the entry of Mtb into monocytes in T2D patients (Restrepo et al., 2014). These 
defects could be responsible for the increased susceptibility of T2D patients to TB. 
In this study, patients with TB were followed up to month two of TB treatment. Month 
two is a crucial timepoint for patients undergoing TB treatment because sputum smear 
conversion occurs during this timepoint (Azarkar et al., 2016). A delay in sputum smear 
conversion is associated with an increase in bacterial load and in some instances an 
indicator of treatment failure and resistance to TB treatment (Singla et al., 2003; 
Kuaban et al., 2009; Unsematham and Kateruttanakul, 2013). Increased 
mycobacterial load is also associated with disease comorbidities such as T2D (do 
Socorro Nantua Evangelista et al., 2018). TB patients with T2D also present with a 
high Mtb load, delayed sputum smear conversion and are more likely to fail TB 
treatment (Stevenson et al., 2007; Jeon and Murray, 2008b; Riza et al., 2014). 
However, TB-T2D patients from this study were sputum culture negative at month 2 
and the patients were not followed up until the end of treatment. In this study we could 




The immune system is a complex system and is carefully orchestrated by the 
cytokines produces by all cells of the body. Cytokines are secreted by immune cells in 
response to an antigen and they play an essential role in the recruitment and activation 
of immune cells and they also facilitate cellular processes such as cell division and 
cell growth. Chemokines are a subset of cytokines known as chemoattractant 
cytokines responsible for the recruitment of immune cells from the peripheral into the 
tissue. They achieve this function by binding to their receptors expressed on the cell 
membrane of all leukocytes. Chemokines are grouped according to their structure and 
function with the CC and CXC subgroups consisting of most of the chemokines. CC 
and CXC ligands are expressed in the bone marrow and thymus revealing their role in 
the development, maturation and differentiation of immune cells (Liu et al., 2006; 
Misslitz et al., 2004; Serbina and Pamer, 2006).  
In chapter 3, heatmaps were generated to cluster serum host immunological markers 
based on their mean concentration for each patient group. In cluster 1, the 
concentration of MDC and MIP-1β, belonging to the CC family, and CXCL9/MIG, 
belonging to the CXC family, are increased in HCs in comparison to T2D and TB 
patients at baseline. This finding suggests that TB disease caused by Mtb and T2D 
driven by hyperglycaemia and insulin resistance may contribute to impaired 
chemotaxis of immune cells to lung during infection. Although no statistical 
significance was found in the TB-T2D group, they had a similar trend in mean 
concentrations as the TB and T2D group. MDC concentrations are directly correlated 
to monocyte frequencies (Godiska et al., 1997). This further supports our claim of 
defects in chemotactic function at the early stage of TB disease, as the MDC 
concentration increases in patients with TB (TB and TB-T2D group) at month two of 
treatment as represented in Figure 3.8.  
TB patients with T2D have been reported to present with a greater extent of disease 
severity in comparison to TB patients without T2D (Jeon and Murray, 2008b). MMP-3 
is a protein involved in the degradation and the breakdown of the extracellular matrix 
facilitating tissue remodelling, cell migration and recruitment and by so doing, 
modulating chemokine and cytokine signalling (Page-McCaw et al., 2007). MMP-3 
also plays a role in tissue repair in diseases where tissue damaged occurred as a 
result of chronic inflammation (Ugarte-Gil et al., 2013). Their concentration increases 




with lung tissue damage and anti-TB therapy is known repair tissue damage. We 
hypothesize that the increase of MMP-3 concentrations in the TB-T2D group during 
treatment is suggesting the body is trying to repair the greater tissue destruction that 
has been reported to be present in these patients. It is most likely due to a positive 
feedback mechanism, whereby the body produces more MMP-3 to compensate for 
tissue damage. In latently infected hosts with T2D, T cell activation is delayed while 
Th1 and Th17 responses increase in TB-T2D patients in response to an Mtb antigen 
(Restrepo and Schlesinger, 2014). The production of CXCL9/MIG, MDC and MIP-1β 
are T cell dependent and the reduction in the concentration of these chemokines 
highlights the impairment of T cell responses in TB and T2D patients. While in the TB-
T2D group the concentration of CXCL9/MIG and MIP-1β is low at the initiation of TB 
treatment and increases at month two of TB treatment. Mtb-specific T cell responses 
are essential for macrophage activation, however at baseline in TB patients the 
concentration of MIP-1β and MDC which are responsible for monocyte recruitment are 
decreased in these patients. MIP-1β has been used in TB biomarker to distinguish 
between patients infected with TB and patients with TB disease (Yao et al., 2017). TB 
patients have a higher Mtb load than latently infected individuals. Although, this was 
not the focus in our study, it correlates with our finding where there are increased 
concentrations in TB patients at baseline. 
Th1 immune responses form part of cell-mediated immunity and the activation of 
macrophages. Macrophage frequencies are altered in TB-T2D patients (Lopez-Lopez 
et al., 2018) and their phagocytic ability is impaired (Raposo-García et al., 2017). Due 
to the chronic inflammation present in TB-T2D, there is a decline in Th1 immune 
responses, and this could explain the decreased concentrations of sIL-4R in T2D and 
TB-T2D patients. A finding by Chang et al. 2012 can further justify our speculation 
where they showed that IL-4 can regulate glucose and lipid metabolism. T2D patients 
are characterized to have high glucose and lipid concentrations and T2D patients in 
this study had lower concentrations in comparison to HC. 
sIL-4R and complement C5a had a similar effect in the different patient group and form 
part of cluster 3. In the introduction section of this chapter, we highlighted role of the 
complement system in the context of its receptors and their role in opsonisation. The 
defects in opsonisation were correlated to the defects in complement receptors and 




complement C5a in our study was lower in TB patients with T2D in comparison to TB 
patients without T2D. This can further validate the role of the complement system 
during opsonisation, where TB-T2D patients phagocytic ability of cells is impaired 
resulting in an increase in Mtb load associated with disease severity in these patients.  
Eotaxin is an eosinophil specific chemoattractant responsible for the recruitment of 
eosinophils to the site inflammation. Eosinophils can generate and store eosinophil 
specific toxins in granules and are referred to as eosinophil granular proteins, these 
proteins are increased in patients with TB (Moideen et al., 2018) and are associated 
with ROS generation. We found eotaxin concentrations to be lower in TB patients 
compared to HCs. Furthermore, no change in serum concentration was observed in 
TB patients during TB treatment. Although literature reports high eotaxin 
concentrations in TB patients, our results are contradictory to what is commonly 
reported on eotaxin in the context of TB. However, a study done by (Choi et al., 2016) 
confirms our result as they also observed low concentrations of eotaxin in TB patients 
at baseline. Interestingly, their study was also conducted on a South African 
population. They also observed a treatment response in TB patients whereby the 
eotaxin concentrations increased with TB treatment. We did not observe this in our TB 
patients, but their study participants were triple our numbers and maybe it is due to 
our low statistical power that were did not observed a treatment response in TB 
patients.  
Apo AI and Apo CIII are protein components of HDL which are involved in glucose 
metabolism through the secretion of insulin from pancreatic β cells (Drew et al., 2009). 
Apolipoproteins are involved in the translocation of GLUT4 to the cell surface. Apo AI 
increases glucose disposal in skeleton muscle supporting the role of HDL in reducing 
insulin resistance (Tang et al., 2019). Apo CIII is also associated with insulin 
resistance, inflammation and β cell failure in T2D (Åvall et al., 2015). The concentration 
of Apo AI and Apo CIII were lower in TB patients with T2D in comparison to TB patients 
without T2D. TB patients are associated with low HDL concentrations (Akpovi et al., 
2013; Gebremicael et al., 2017). However, one of the limitations in this study were, we 
did not measure the lipid concentrations of TB patients and we therefore cannot 
speculate on whether their lipid profile would correlate with the observed high 
concentrations of Apo AI and Apo CIII. The concentrations of Apo CIII decrease in TB 




concentration increases in the TB-T2D group. Apo CIII is corelated with the 
mechanistic features driving T2D and hence why treatment does not seem to decrease 
their concentration.  
High concentrations of Apo A1 and Apo CIII are associated with inflammation and 
correlate with inflammatory markers such as SAP and ER stress (Botteri et al., 2017; 
Wu et al., 2019). In this study the concentrations of Apo CIII was higher in TB patients 
compared to TB-T2D patients at baseline and both Apo A1 and Apo CIII significantly 
decrease from baseline to month two of treatment in TB patients only. The decrease 
in Apo AI and Apo CIII could be associated with inflammation as inflammation 
decreases during TB treatment as observed by the decline in inflammatory markers.  
Alpha-1-antitrypsin (ATT) is correlated with poor lung function, failure to respond to 
anti-TB treatment and severity of TB disease (Levy et al., 2007; Almeida et al., 2009; 
de Melo et al., 2019). Our results correlate with previous findings, as ATT 
concentrations are higher in TB and TB-T2D patients at baseline and decrease two 
months into treatment. CRP and SAA are inflammatory markers and CRP is widely 
used as an indicator of inflammation. Inflammation is increased in TB and TB-T2D 
patients at baseline and the inflammation decreases two months into TB treatment. 
5.2 B cell phenotyping in TB patients with and without T2D 
B cells are the primary coordinators of the humoral immune response, however their 
immunological function within T2D remains poorly defined. It has been shown that in 
T2D patients exposed or infected with Mtb have altered frequencies of naїve and 
activated B cells (Kumar et al., 2015). Our group also found that the absolute number 
of B cells in TB-T2D patients was lower than that of TB patients (unpulished). This 
study therefore aimed to investigate known published phenotypes of B cells in relation 
to TB patients with T2D. One of the beneficial characteristics of the adaptive immune 
system is immunological memory. During TB disease this proves crucial in order to 
mount an effective and rapid immune response upon encountering Mtb. B cells can 
also utilize this function and we investigated the resting and activated memory B cell 
ratios. 
HCs and TB-T2D patients at baseline expressed similar ratios between the resting 




T2D and TB patients although there are higher concentrations in resting memory B 
cells in T2D. The activated memory B cells are lower in T2D and TB patients at 
baseline. Activated memory cells are effective in regulating a fast and effective 
immune response. Memory B cells have two main functions, one they act as APCs 
and secondly, they secrete cytokines in response to an antigen. The low frequency of 
effector memory B cell observed in T2D patients in comparison to the resting memory 
B cells could result in the dysregulation of the above-mentioned functions resulting in 
an altered immune response. 
Apoptosis is beneficially to the host as it removes potentially autoreactive immune cells 
from the peripheral and in tissues controlling the number of activated immune cells in 
response to a pathogen. The FasL-Fas pathway was previously associated with 
natural killer cells and CD8+ but the Fas receptor is also expressed on activated B 
cells (Hahne et al., 1996; Schattner and Friedman, 1996).  
Naïve B cells expressing the apoptotic phenotype of CD125+CD178+ are increased in 
TB patients and lower in HCs and T2D patients. FasL is highly expressed by CD5+ B 
cells (Yang et al., 2013) and our group defined CD19+IgM+ as killer B cells (van 
Rensburg et al., 2017) and in this study the killer B cell phenotype was defined as 
CD19+CD5+IgM+CD38+CD125+CD178+. A similar response as the naïve B cells was 
observed with the killer B cell phenotype. However, the expression 
CD19+CD125+CD178+ in TB patients decreases two months into anti-TB treatment 
while the killer B cells of TB patients increases at the two-month mark. 
Bregs have immunosuppressive properties, a function they achieve through the 
secretion of anti-inflammatory cytokine IL-10. The frequency of Bregs is higher in TB 
patients at baseline compared to T2D patients. There were differences between the 
study groups in Bregs expressing the apoptotic phenotype at the initiation and at 
month of TB treatment. IL-10 serum concentrations although not correlated with the 
phenotypic data had an opposite effect where the levels were higher in TB patients 
and lower in T2D patients. This correlates with a finding by Winer et al. where the B 
cells of obese individuals linked to insulin resistance resulted in the decreased 
production of IL-10. 
B cells have a high expression of MHC II on their cell surface allowing them to exercise 




data, the T cell responses were declined in T2D patients more especially the Th2 
responses. CXCR5 a receptor for CXCL9/MIG is involved in B cell differentiation, 
activation and antibody production (Schaerli et al., 2000; Kim et al., 2001) and 
activation via the CXCR5 accelerates B cell immune responses (MacLeod et al., 
2011). The serum concentrations of ligand CXCL9/MIG were decreased in T2D 
patients whose response is Th2 driven. 
Conclusion 
The immunological responses in TB, T2D and TB-T2D patients are dysregulated and 
improve at month two of TB treatment in TB and TB-T2D patients. Markers associated 
with cell proliferation, cell development, chemotactic function, granuloma formation 
and monocyte recruitment were dysregulated. Notably, Th2 responses the prime 
immune response during Mtb infection and regulators of inflammation are 
downregulated. Immunological analytes associated with disease severity, cell 
recruitment and opsonisation were also dysregulated in TB patients with T2D. The 
memory response, regulatory and apoptotic function through the expression of FasL 
and IL-5Rα in B cells is impaired in T2D patients and TB patients at baseline. There 
were limitations in this study as study participants differed between the cytokine 
profiling and phenotypic cohorts and hence there was direct correlation conducted. 
The TB-T2D patient numbers were extremely low in this study and hence there was a 
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TANDEM – Concurrent Tuberculosis and Diabetes Mellitus: Unravelling the causal link 
and improving care 
  
Stellenbosch University Ethics Committee project number: 





We would like to ask you to take part in a study which investigates the link between TB and 
Diabetes. The study forms part of an international project funded by the European Union , 
which will investigate over 2000 participants in four different countries (South Africa, 
Indonesia, Romania and Peru). Your participation is entirely voluntary and you are free to 
decline to participate. If you say no, this will not affect you negatively in any way whatsoever. 
We will explain the study to you. Please ask questions so that you understand clearly what 
this is about. You are under no obligation to give permission for this study. If you agree to take 
part, please read this form and sign the consent sheets at the end. Please tick off every box, 
if you agree. This study has been approved by the Health Research Ethics Committee (HREC) 
at Stellenbosch University (contact person Elvira Rohland at 021 938 9677 or elr@sun.ac.za) 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
 
The contact details of the investigator are as follows: Dr. Gerhard Walzl, Division of Medical 
Biochemistry, Stellenbosch University, Phone number: 021-9389158 or 0825923212.  
 
 
What are TB and Diabetes? 
 
Tuberculosis (TB) is a disease caused by a germ, and is spread by coughing.  TB affects 
adults and children, and mostly causes disease in the lungs. Household contacts of TB 
patients and people infected with HIV are at increased risk of being infected with TB and 
getting TB disease. When someone comes into contact with a person who is ill from TB, they 
have a high risk of also getting infected with TB. Infection means that they have the TB germ 
in their body, but will not necessarily get ill (TB disease) from it.  TB disease causes cough, 
breathing problems, weight loss and fever. Without treatment TB can be deadly, but with 
treatment you will usually get better. Many TB patients also have diabetes mellitus (DM), a 
disorder with how sugar is processed in your body. Early on diabetes has no symptoms, so 
many people do not know they have this condition. Screening DM among TB patients is not 
yet routinely performed. Also treating two conditions is not easy, TB drugs can temporarily 
worsen diabetes and, diabetes may worsen TB treatment outcome. Through this project we 
would like to understand more about the link between TB and DM and identify how to improve 







What is the purpose of the Study? 
 
The purpose of this study is to answer a number of practical questions about how to diagnose 
DM in people with TB, how best to control blood sugar levels in people with TB and DM and 
to understand how these two diseases are related. Study participants diagnosed with TB will 
also be checked for DM and those with DM will be checked for TB. Then, if you are diagnosed 
as having both TB and DM, we will refer you to the respective clinics to treat both conditions 
and will follow you up until 1 year after you finish your TB treatment. For this study we will 
recruit 500 TB patients, 100 Diabetes patients and 100 healthy individuals. 
 
 
Why have you been chosen to participate in this study? 
 
You have been chosen to participate in this study, because you have been diagnosed with 
TB, Diabetes, HIV, or you are a healthy control participant. 
 
What tests are we planning to do? 
 
We anticipate that you will be in this study for 18 months (12 months after completing TB 
treatment). If you are a participant with Diabetes who does not have TB or if you are a healthy 
participant then we will only see you once during this study. 
 
We will take you for a Chest X-ray at time of recruitment and if you have TB also end of 
treatment (usually 6 months) and at 12 months after completing TB treatment (18 months). 
For diabetic and HIV patients, we shall also do a sonar test of the blood vessels in your arm– 
only once if you have diabetes, and at day 0, month 12 and month 18 if you have HIV.  We 
will  collect the following body fluids on day 0 (recruitment), week 1,2, month 1,2,4,5,6,9,12,15 
and 18. For some participants there will be fewer time points and fewer body fluids collected 
and you will be informed at the beginning of the study which time points points/body fluids will 
be left out): 
 
-  sputum (10ml or about  two teaspoons full) 
-  blood (70ml or  14 teaspoons) 
-  urine (20ml or  4 teaspoons) 
 
You will undergo a DM screening process. This involves a questionnaire and testing your 
blood and urine for sugar. For this purpose some of the blood we will collect and a urine 
sample will be sent to the lab. We also perform a finger prick test. Your sputum, blood, urine 
will also be tested for how your body responds to treatment. Some of the tests done on your 
specimen will include studying your genetic material, also called DNA or RNA. Our genes 
determine what we look like and sometimes what kind of diseases we may be susceptible to. 
During this study we will try to find genes that make us more susceptible to TB and diabetes. 
We will also determine your ancestry in other words how much of your genetic material is from 
white, black African, Asian, Khoi-San ancestors. After completion of TB treatment we would 
like to continue to check on your health regularly (every 3 months until 12 month after 
completion of TB treatment). 
 
We will also ask your consent to do an HIV test on you.  The HIV test results will be available 
immediately, and if the test is positive, we will confirm the result with another test. This second 
result will also be available immediately. Before we do the HIV test, the study nurse who will 
draw the blood will counsel you about the implications of this test result. After the test has 
been done and you know the result, we will counsel you again. This process is called “pre-and 
post test counselling”. It is important to know your HIV status as there is treatment available 
which can help you a lot although the treatment cannot cure HIV. We would refer you to the 




for care. At these clinics, good treatment for HIV infection (anti-retroviral therapy) is now 
available to those patients who need it. 
If you have previously been diagnosed with HIV, we shall do a confirmation test for our records. 
 
What are the implications of this study for you? 
 
If you decide to take part in this study you will have to return to the clinic for follow up visits. 
Your participation in the study would be ended if you missed follow-up appointments. 
You will not be paid to take part in this study. Although some remuneration for expenses 
occurred incl. transportation and loss of income will be given to you for your effort and time 
(approx. R 100). 
 
What are the benefits to your taking part of this study? 
 
No individual study results from this study will be available for participants, as this type of result 
does not offer a benefit to individuals at this stage. We do hope however that the results will 
benefit the communities that are affected by TB and Diabetes. 
 
What are the potential risks of this study for you? 
 
We will not perform genetic analysis of any underlying medical conditions except TB and 
Diabetes. We will not perform any analysis related to paternity testing. Therefore the outcome 
of the analysis has no implications for you or your family. 
 
The only discomfort you may experience is from a pinprick in your finger and the blood draw. 
Both will be minor.  
 
If you cannot produce enough sputum we will perform a procedure called ‘induced sputum’ 
collection. For this test you will be asked to breath in a salt solution through a nebulizer, similar 
to the ones used by asthmatics. Some people may develop transient breathing difficulties but 
we will have a trained nurse and the necessary medication on site to deal with this. 
 
We may store some of your samples in a freezer for future testing if necessary. The blood and 
other body fluids will be stored for up to 10 years, but will only be used for this specific research 
project. Most of the samples will be sent to a laboratory in another country for some specialized 
tests since these tests are not available in South Africa. These laboratories will be part of this 
project. Should you decide to withdraw your consent at a later stage, you may ask for the 
destruction of your samples that were obtained from you earlier than this date. After 10 years 
your samples will either be destroyed or we will remove any link to your identity from the 
samples so that it can never be traced back to you.  
 
How will your confidentiality be protected? 
 
All information about you will be kept private and confidential. Your name will not accompany 
the material that we send away and will never be made public. Information of your genetic 
make up will not be made available to anyone. Members of the Research Ethics Committee 
may inspect the research records. 
 
 
Whether you choose to participate in this study or not, will have no effect on your treatment 
whatsoever. If you would like to withdraw from this study, you may do so at any time point and 
this too will have no negative implications on your treatment.  
 
 








Dr. Walzl and the study team. 
Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch 
University and Tygerberg Hospital, Francie van Zijl Drive, Parow. 







INFORMED CONSENT FORM:  
TANDEM  
 
Please read, tick off each of the boxes and sign the form if you agree to take part in this 
study. 
 
1. I understand what this study is about and know how to contact the 
investigators if I want to. 
 
2. I understand that body fluids (blood, sputum, urine)    will be collected from 
me/the participant and that tests incl. genetic analysis will be done. 
 
3. I understand that all the information given to the investigators and all test 
results will be kept private and confidential. 
 
4. I understand that I will not benefit financially from this study apart from being 
compensated for transport costs and loss of income on the days that I take 
part in the study. 
 
5. I understand that I am free to withdraw myself/the participant from this study if 
I want to. 
 
6. I understand that if I refuse to take part in this study, that my/the participant’s 
care will not be affected. 
 
7. The information was explained to me by: 
 
 
Name of participant:  
 
 














Tick the option you choose: 
 
I agree that my blood or tissue sample can be stored indefinitely after the 
project is completed but that it is anonymised with all possible links to my 




research in this or a related field. Once my sample is anonymised, my rights 
to that sample are waivered. My sample may be shipped to another 




 Please destroy my blood sample as soon as the current research project 
has been completed.   
 
 




 ..............................................................   .......................................................  





 INFORMED CONSENT FORM- HIV TESTING:  
TANDEM 
1. I give my permission for the investigators to do a HIV test on me/the participant. 
 
2. I have received pre-test counseling, understand what HIV is about, and realize the 
implications of this test for me/the participant. 
 
3. I understand that the investigators will perform a confirmatory test after a positive 
first test and that they will inform me of the final test result during the first visit. 
 
4. I understand that if I refuse permission for HIV testing, my/the participant’s care will 
not be affected. 
 
Name of participant:  
 
 
Address of participant:  
 
 
Signature of participant/legal guardian:  
 
 
Name of person giving consent 
 
 
Capacity in which consent is given 



























I, ……………………………………………………………………..(name)  
 
in my capacity as……………………………………(researcher/researcher representative) 
declare that: 
 
1. The information in this document was explained to ………………………………………            
 (name of the participant/representative). 
 
2. I have given him/her the opportunity to ask further questions regarding the study and 
aspects of participation. 
 
3. The information was given in …………………………………(language) and no 
translator was used. 
 
 
Signed:  
 
 
 
Place: 
 
 
 
Date:  
 
 
 
Witness:  
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